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1 Introduction 
 
 
1.1 Iron 
Iron is an essential micronutrient for humans and other life forms (Oshiro, Morioka et 
al. 2011). Its ability to switch between the ferrous, Fe(II), and ferric, Fe(III) makes it 
indispensable as well as hazardous. Iron is a component of several enzymes and 
takes part in many vital biochemical activities, such as oxygen transport, energy 
metabolism and DNA-synthesis (Papanikolaou and Pantopoulos 2005).  
The human body contains approximately 3-5g of iron, with more than two thirds 
found in hemoglobin, the protein of red blood cells. Around 20-30% of the body iron 
can be found in the liver and reticuloendothelial macrophages (Papanikolaou and 
Pantopoulos 2005; Oshiro, Morioka et al. 2011). The remaining body iron is localized 
in myoglobin, a protein that carries oxygen to muscles and in iron-containing proteins 
and enzymes (Papanikolaou and Pantopoulos 2005; Gkouvatsos, Papanikolaou et 
al. 2011)  . The daily amount of absorbed iron from the diet is limited to 1-2 mg, 
which compensates for nonspecific iron losses (urine, stool, sweat) (Papanikolaou 
and Pantopoulos 2005; Supplements 2007).  
Since there is no physiological pathway for iron excretion in humans, the 
maintenance of iron homeostasis and its regulation are necessary. Under 
physiological conditions extracellular iron is bound to plasma transferrin (Tf), in order 
to remain soluble and nontoxic (Papanikolaou and Pantopoulos 2005). Usually only 
one third of the circulating transferrin binds to iron, allowing the remaining Tf to buffer 
any alterations of iron levels. Under pathological iron overload Tf becomes fully 
saturated and unbound iron remains redox-active and thus toxic. An excess of iron 
induces the formation of radicals, which lead to cell death and tissue damage 
(Gkouvatsos, Papanikolaou et al. 2011). 
 
 Iron Chelators 1.1.1
Iron chelators can reduce elevated levels of iron. Thus, organ damage caused by 
free iron can be prevented (Kwiatkowski 2008). The chelating agent could either form 
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a non-toxic complex with iron, which can be excreted or cover the metal at its protein 
binding side to suppress any redox activity (Gaeta, Molina-Holgado et al. 2011). 
At this time, three iron chelators, Deferoxamine, Deferiprone and Deferasirox, 
are available for clinical use (Kwiatkowski 2008). 
Deferoxamine (Formula 1) is 
produced in Streptomyces pilosus and 
has been used for over 40 years in 
patients with iron overload 
(Kwiatkowski 2008; Cappellini and 
Pattoneri 2009). It is a hexadentate iron 
chelator, which binds iron in a 1:1 ratio. This complex is then excreted in urine and 
faeces.  Unfortunately Deferoxamine is barely absorbed from the gastrointestinal 
tract and has a very short half-life. Therefore, it has to be administrated 
subcutaneously or intravenously. The route and period of administration (over 8-24 
hours, 5-7 days per week) led to the search for orally active iron chelators with a 
longer half-life (Kwiatkowski 2008). 
Deferiprone (1,2-dimethyl-3-hydroxypyrid-4-one), the first orally active chelator 
was synthesized in the early 1980s (Formula 2). This chelating agent 
is hydrophilic and rapidly absorbed (Cappellini and Pattoneri 2009). 
Being a bidentate chelator it forms a 3:1 complex with iron, which is 
excreted in urine (Kwiatkowski 2008). Data from different studies 
showed that levels of other bivalent metals were not reduced 
significantly (Cappellini and Pattoneri 2009). Deferiprone has to be 
taken three times a day due to its short plasma half-life (1.5-2.5 
hours). Unlike Deferoxamine, Deferiprone can cross cell-membranes and therefore 
protect organs, such as the heart and liver from iron 
overload (Cappellini and Pattoneri 2009). Adverse 
effects, such as neutropenia, and in rare cases 
agranulocytosis limit the use of deferiprone 
(Kwiatkowski 2008).  
Deferasirox (Formula 3) is a novel, orally active 
iron chelator, which has to be taken only once a day 
(Kwiatkowski 2008). The active molecule is a highly 
Formula 1 Deferoxamine 
Formula 2 
Deferiprone 
Formula 3 Deferasirox 
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lipophilic, N-substituted bis-hydroxyphenyl-triazole (Cappellini and Pattoneri 2009). 
The absorption from the gastrointestinal tract is rapid and the half-life, long (7-16h). 
Moreover Deferasirox has a high specificity for iron, with minimal affinity for other 
bivalent metals (Kwiatkowski 2008). It is able to remove iron from liver tissue. The 
tridentate chelator binds iron in a 2:1 ratio (Cappellini and Pattoneri 2009). Iron 
bound to Deferasirox is excreted in faeces (Kwiatkowski 2008). Reported adverse 
effects of Deferasirox include nephrotoxicity (Sanchez-Gonzalez, Lopez-Hernandez 
et al. 2011). 
 
 Fields of application – Diseases of iron overload 1.1.2
Hereditary hemochromatosis (HH) is the most common hereditary disease in 
populations of European ancestry (Sheftel 2001). It is an autosomal recessive 
disorder, which leads to an increased absorption of iron from the gastrointestinal 
tract. The excessive iron accumulates in different organs, causing severe damage. In 
most cases, HH results from a mutation of the HFE-gene, which plays an important 
role in the production of hepcidin (Papanikolaou and Pantopoulos 2005). Hepcidin, a 
liver-derived peptide hormone, is a regulator of iron homeostasis, preventing 
inappropriate high iron absorption. Circulating hepcidin is increased in the presence 
of iron and inflammation. In contrast, hepcidin levels are depressed in states of iron 
deficiency (Gkouvatsos, Papanikolaou et al. 2011). In patients with HH, hepcidin 
levels are low, despite of iron overload in several organs (Sheftel 2001). 
Accumulated iron is usually observed after the age of 40, mainly in the liver, but also 
the pancreas, heart and skin (Papanikolaou and Pantopoulos 2005). 
A subtype of HH is juvenile hemochromatosis (JH), where a nonsense 
mutation in the hepcidin gene (HAMP) is responsible for the onset of the disease 
(Gkouvatsos, Papanikolaou et al. 2011). Patients suffering from JH will show 
symptoms before the age of 30 (Papanikolaou and Pantopoulos 2005). 
Secondary iron overload develops in patients, who regularly receive blood 
transfusions (Sheftel 2001). Red blood cell transfusions are used for the treatment of 
chronic anemias, such as β-thalassemia mayor, sickle-cell disease, pyruvate kinase 
deficiency and other rare anemias (Kwiatkowski 2008). A unit of transfused blood 
contains 200-250mg of iron and patients with chronic anemias receive transfusions 
usually every 3-4 weeks (Kwiatkowski 2008; Cappellini and Pattoneri 2009). 
Moreover, in patients with ineffective erythropoiesis, iron absorption from the 
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gastrointestinal tract is highly increased (Kwiatkowski 2008). Regular administration 
of red cell transfusions and the inability of the human body to actively excrete iron 
lead to the accumulation of iron (Cappellini and Pattoneri 2009). 
Iron overload is a critical state that harms the organism. Elevated levels of iron 
lead to cardiac toxicity, which is the leading cause of death in patients with iron-
overload. Other affected organs are the liver and the endocrine system, resulting in 
complications, such as fibrosis, cirrhosis, growth failure and diabetes mellitus, 
respectively (Kwiatkowski 2008). 
 
 Treatment of neurodegenerative diseases 1.1.3
Elevated levels of redox active metals are found in the brain of patients with 
neurodegenerative diseases (ND), such as Alzheimer’s disease, Parkinson’s disease 
and Friedreich’s ataxia (Hider, Roy et al. 2011).  Chelation therapy is a reasonable 
approach to reduce the toxic levels of these metals, particularly iron. Therefore it is 
necessary to design chelating agents, which are able to cross to blood-brain-barrier 
and reach the brain (Hider, Ma et al. 2008).   
 Age is the main cause of most ND and this may be directly linked to oxidative 
stress. The definition of oxidative stress is described as an imbalance between the 
production and manifestation of free radicals and the organisms’ ability to detoxify 
these reactive species through several enzymes, including superoxide dismutase, 
catalase and glutathione (Hider, Roy et al. 2011). 
Reactive oxygen species (ROS) are small and highly unstable molecules, 
which contain oxygen. In order to become stable, free radicals are very likely to 
interact with molecules in the cell (lipids, protein, DNA), causing cytotoxicity. The 
most important free radicals are superoxide (O2.-), peroxide (O2-) and hydroxyl radical 
(OH.). ROS are by-products of metabolic processes in the human body (Pantopoulos 
and Hentze 1995). Two major sources of ROS production are the mitochondrial 
respiratory chain and the cytochrome P450 mixed-function oxidases, a group of 
enzymes in the liver (Wu and Cederbaum 2003).   Moreover, hydroxyl radicals can 
be generated by excessive free iron via the Fenton reaction (Fe2+ + H2O2  Fe3+ + 
OH. + OH-). Thus elevated levels of unbound iron contribute to ROS production and 
oxidative stress (Molina-Holgado, Gaeta et al. 2008). Furthermore, free radicals from 
the environment, such as from radiation, smog, UV light or tobacco smoke, should 
not be neglected (Wu and Cederbaum 2003). 
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When the antioxidant capacity of the human body is reached, oxidatively 
modified molecules accumulate in cells, harming them and even leading to cell death 
(Hider, Roy et al. 2011). Compared with other organs, the brain is much more prone 
to oxidative damage due to its high consumption of oxygen and glucose, which leads 
to the production of reactive oxygen species. In addition, the levels of both iron and 
ascorbate are high, whereas levels of antioxidant protecting enzymes are low (Floyd 
and Hensley 2002).  
 In Europe around 10 million people have dementia, where the majority are 
diagnosed with AD and 1.2 million people suffer from PD (EPDA 2012; Parlament 
2012). Both major neurodegenerative disorders, AD and PD, are associated with 
protein aggregation and oxidative stress (Gaeta, Molina-Holgado et al. 2011). In both 
of these metabolic alterations metal ions, such as iron and copper, are involved 
(Molina-Holgado, Gaeta et al. 2008). Moreover genetic factors play a role, as 
mutations in genes encoding aggregating proteins, such as amyloid beta protein and 
α-synuclein lead to inherited forms of AD and PD (Hider, Ma et al. 2008). 
Alzheimer’s disease (AD) is the most common form of dementia. It is a slowly 
progressing disease of the brain, which cannot be cured (Oshiro, Morioka et al. 
2011). AD usually occurs after the age of 60. The risk of developing AD correlates 
with age and is between 10-15% at the age of 65. The risk rises even up to 50% for 
those over the age of 85. Moreover, there is also a form with an early onset. In this 
case, genetic factors play a major role and symptoms can occur at the age of 30-40. 
Nevertheless, both forms have similar symptoms, including mild cognitive impairment 
and loss of memory in early stages. Later on, affected people lose the ability to cope 
with everyday functions, such as dressing, standing, walking, and even swallowing. 
In addition, the behaviour changes and patients can become depressed or 
withdrawn, or on the other hand, depressive or hostile (Burd, Fraser et al. 2001). The 
AD brain is characterized by insoluble aggregates of amyloid beta protein between 
nerve cells and neurofibrillary tangles inside the neurons (Burd, Fraser et al. 2001; 
Oshiro, Morioka et al. 2011). Furthermore, the levels of the neurotransmitter 
acetylcholine are low in brain regions, which are responsible for short-term memory, 
memory storage and behaviour (Burd, Fraser et al. 2001).  
Parkinson’s disease is a slowly developing neurodegenerative disorder, 
affecting the movement, with no cure. There are also two forms, comparable to AD, 
the familial and the sporadic form. The familial form is caused by genetic mutations 
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with an early onset, around the age of 40. The causes of the sporadic form are for 
the most part unknown. Risk factors such as, age, gender (men are more often 
affected then women) and environmental influences play a role. The average age of 
outbreak is around 60 years (Burd, Fraser et al. 2001). Parkinson’s disease (PD) is 
caused by the death of dopamine-generating cells in the substantia nigra (SN) and 
elevated levels of acetylcholine in the striatum (Oshiro, Morioka et al. 2011). 
Dopamine is a neurotransmitter, which is necessary for normal muscle activity. 
Therefore the cardinal symptoms of PD result from altered muscle function (Burd, 
Fraser et al. 2001). Moreover, Lewis bodies, intracytoplasmic inclusions in the SN, 
are considered as the hallmark of PD and consist mostly of phosphorylated α-
synuclein (Oshiro, Morioka et al. 2011). 
 Patients suffer from tremors in the hands and feet, rigidity, bradykinesia due to 
excessive muscle contraction caused by decreased dopamine levels (Burd, Fraser et 
al. 2001; Oshiro, Morioka et al. 2011). Non-motor symptoms include cognitive 
impairment, mood swings and sleep disturbances. Many affected people also suffer 
from depression (Oshiro, Morioka et al. 2011). 
 
 Design of iron chelators 1.1.4
Iron chelators for clinical use must fulfil many criteria, with metal selectivity being of 
upmost importance. Moreover membrane permeability is important in order to reach 
the target tissue and oral activity is advantageous. Factors like lipophilicity, molecular 
size and ionization state affect the permeability of membranes and need to be 
considered (Liu and Hider 2002). First of all the target metal has to be identified. 
Pathogenesis and progression of neurodegenerative diseases are complex and 
many factors are involved. However, iron could be assigned as the main target in PD. 
In contrast, in AD also copper and zinc play a crucial role in the progression of the 
disease and designing a chelator suitable for these metals is intricate and the toxic 
potential will be high (Gaeta and Hider 2005).  
 In the design of iron chelators the oxidative state of the target metal is 
important and affects the choice of the donor atoms. Iron(II) selective chelating 
agents possess nitrogen or sulfur atoms as ligands, whereas chelators with high 
affinity for iron(III) contain oxygen atoms as ligands (Gaeta and Hider 2005). Iron(II) 
selective chelators will bind other essential bivalent metals, such as zinc, copper and 
cobalt to a certain degree, which can result in toxicity. In contrast, most tribasic 
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cations, including aluminium and gallium, are not essential to living cells, because 
they have no vital functions. This renders iron(III) as the preferred oxidative state for 
iron chelation (Liu and Hider 2002).  
 
Figure 1  Schematic representation of chelate ring formation in metal-ligand complexes (taken from Liu and Hider (2002). 
  Chelating agents, not only possess different donor atoms, moreover the 
number of the ligands can vary. Chelators with two, three, six or more ligands can be 
classified as bi-, tri-, hexa- or multidentate chelators, as shown in Fig. 1 (Gaeta and 
Hider 2005). Regarding BBB permeability and oral absorption the size of the 
chelating agents should be < 300 kDa, thereby excluding hexadentate chelators. 
Moreover molecules should be uncharged and possess appreciable lipid solubility 
(log P > -0.7) in order to penetrate membranes (Liu and Hider 2002). 
 Generation of non-toxic chelating agents is crucial for clinical use. Toxicity can 
result from many factors, which need to be considered, such as inhibition of iron-
containing metalloenzymes, lack of metal selectivity and redox cycling of iron 
complexes between the iron(II) and iron(III), which generates free hydroxyl radicals. 
Moreover kinetic liability of iron complexes can lead to redistribution of iron causing 
cell injury and death (Gaeta and Hider 2005). 
 The group of bidentate hydroxypyridin-4ones are suitable for therapy of PD, 
because they possess high affinity for iron(III) and form neutral 3:1 complexes under 
physiological conditions. The main problem is the kinetic liability which in principle 
can lead to the generation of free hydroxyl radicals. Different substitutions at the 
pyridinone ring can affect the properties of the chelating agents and lead to effective 
compounds, with low toxicity (Liu and Hider 2002). 
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1.2 Blood-brain barrier 
 Function of the blood-brain barrier 1.2.1
The blood-brain barrier (BBB) is formed by endothelial cells of the brain capillaries 
(Abbott, Patabendige et al. 2010). It is a selective interface between the blood and 
the central nervous system (CNS) with vital functions, such as protection against 
toxic and noxious compounds. An essential function of the BBB is the maintenance 
of the brain homeostasis by controlling the concentration of ions within the brain 
(Cardoso, Brites et al. 2010). In order to generate optimal conditions for synaptic 
signalling, exchanges between the blood and brain compartments are regulated by 
specific ion channels and transporters (Abbott, Patabendige et al. 2010). Some 
neurotransmitters achieve high levels in the blood plasma, especially after meals or 
exercise, which could be detrimental to the brain tissue if allowed to freely diffuse into 
the brain. Therefore, the BBB has to separate between two pools of 
neurotransmitters, central and peripheral. On that account, the central and peripheral 
nervous system can use similar or the same agents in different concentrations 
without affecting the other (Abbott, Ronnback et al. 2006; Bernacki, Dobrowolska et 
al. 2008). 
 Being a selective barrier, the BBB has to differentiate between nutrients and 
metabolites required by the CNS and toxic or noxious substances. Therefore, the 
BBB possesses a number of efflux transporters to remove unwanted agents, such as 
xenobiotics, some endogenous metabolites and microorganisms (Abbott, 
Patabendige et al. 2010). Essential nutrients can enter the brain through passive 
permeability or specific transport systems in order to keep a constant supply of the 
required substrates (Abbott, Patabendige et al. 2010; Cardoso, Brites et al. 2010).  
 The BBB is present in all brain regions, except those, which regulate the 
autonomic nervous system and endocrine glands of the body. In these areas, blood-
borne molecules can diffuse through fenestrations in blood vessels (Ballabh, Braun 
et al. 2004). 
 
  History 1.2.2
 In 1885, Paul Ehrlich, a German scientist and physician, experimented with 
vital dye and its impact on mammals. The dye was injected intravenously into rats 
and stained all the organs of the body except the brain and spinal cord. He assumed 
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that the brain had less affinity to the dye than the other parts of the body (Ehrlich 
1885). One of Ehrlich’s students, Edwin Goldmann continued Ehrlich’s work. He 
injected trypan blue intravenously observing the same result as Ehrlich. Moreover he 
performed additional experiments where the dye was injected directly into the 
cerebrospinal fluid. This time the CNS was dyed and the other organs remained 
unstained. Goldmann presumed that a barrier must exist between the blood and the 
central nervous system. Max Lewandowsky, a German neurologist, studied the low 
permeability of potassium ferrocyanate into the brain and was the first to use the term 
“blood-brain barrier” (Cardoso, Brites et al. 2010). 
 
  Structure and cell types of the blood-brain barrier 1.2.3
 The BBB is mainly formed by three different cell types: endothelial cells of the 
capillaries, astrocyte’s endfeet, which form a fine lamellae around the capillary 
endothelium and pericytes, which cover up to 30% of the capillaries. Moreover, the 
basement membrane, neurons and neighbouring microglia cells are crucial for the 
proper function of the CNS. Due to their interactions and functions all these cell types 
are constituent parts of the neurovascular unit (NVU) (Fig. 2) (Cardoso, Brites et al. 
2010). 
 Endothelial cells (ECs) are essential for the 
BBB properties, as experiments showed that the 
endothelial layer could not be crossed by 
horseradish peroxidase from either side. 
Furthermore, experiments with amphibian’s 
brains showed a high electrical resistance, 
indicating that they are impermeable to ions. The 
neurovascular unit of amphibians does not 
possess astrocytes, which proved the importance 
of the ECs for the BBB features (Hawkins, 
O'Kane et al. 2006). 
 Astrocytes, whose endfeet envelop the 
capillary endothelium, are necessary for 
proper neuronal function. Moreover astrocytes are able to enhance the charge 
selectivity of ECs by increasing the production of proteoglycan, which forms the 
Figure 2 Schematic representation of the 
NUV (taken from Mensch, Oyarzabal et al. 
(2009). 
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negatively charged glycocalyx (Abbott, Patabendige et al. 2010; Cardoso, Brites et 
al. 2010).  Despite being an important part of the NVU, in some part of the CNS the 
endothelia lack astrocyte envelopment (Abbott 2002). Cell culture experiments, 
where cells were grown in non-contact co-culture using an astrocytes-conditioned 
medium, showed the secretion of factors by the astrocytes. The presence of these 
factors leads to a rise of tight junctional proteins and limits the transport across the 
BBB (Cardoso, Brites et al. 2010). The close association between ECs and 
astrocytes is crucial for the function and properties of the BBB (Abbott, Patabendige 
et al. 2010).  
 Pericytes, vascular smooth muscle cells, cover up to 30% of the endothelia 
and play an important role in the proliferation and differentiation of ECs (Kim, Tran et 
al. 2006; Dore-Duffy 2008). In addition to structural support, pericytes can also 
modulate the permeability of the BBB (Cardoso, Brites et al. 2010). In critical 
situations, such as hypoxia, pericytes migrate away from the microvessels and 
increase the transport across the BBB (Hawkins and Davis 2005).  
 
 Features of the BBB – Tight Junctions 1.2.4
 A key feature of the BBB are tight junctions, which keep macromolecules and 
polar solutes from the entering the brain through paracellular diffusion (Abbott, 
Patabendige et al. 2010). Junctional complexes form a solid barrier by connecting 
ECs tightly together, eliminating gaps and spaces between the cells (Cardoso, Brites 
et al. 2010). Tight junctions and adherens junctions ensure that only a limited number 
of molecules, such as O2 and CO2 can pass the BBB freely. Gap junctions between 
ECs have been identified as a part of the BBB, but their impact on the barrier has yet 
to be discovered (Abbott 2002; Cardoso, Brites et al. 2010). 
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Figure 3 Structure of the BBB tight junctions (taken from Abbott, Patabendige et al. (2010). Further explanation in the 
text. 
 Tight junctions (Fig. 3) are located in the apical area of the ECs and influence 
the properties of the BBB greatly (Cardoso, Brites et al. 2010). The complex structure 
of TJ is formed by various proteins, such as transmembrane proteins occludin and 
claudin (Abbott, Patabendige et al. 2010). These proteins interact with proteins, 
which are located in the plasma membrane of the neighbouring cell, such as ZO-1, 
ZO-2 and ZO-3 (Petty and Lo 2002). Depending on how many times the 
transmembrane proteins span the plasma membrane, they are divided into groups. 
Occludin and claudin have four-pass transmembrane domains and are crucial for the 
tightness of the BBB in contrast to single-pass proteins, junctional adhesion 
molecules (JAM) (Cardoso, Brites et al. 2010). 
 To date, 24 isoforms of claudin are known, with approximately 20-27 kDa 
(Persidsky, Ramirez et al. 2006; Zlokovic 2008). Despite of sharing the four 
transmembrane domains with occludin, both proteins consist of completely different 
amino acids (Cardoso, Brites et al. 2010). Some claudins are essential for the 
maintenance of proper BBB function and experimental data showed that lack of 
claudin-3 or claudin-5 results in a highly permeable BBB (Abbott, Patabendige et al. 
2010). 
 Occludin, a tansmembrane protein of approximately 65 kDa modulates the 
permeability of the BBB to ensure that large, charged and polar molecules cannot 
cross the BBB readily (Furuse, Hirase et al. 1993; Huber, Egleton et al. 2001). 
Moreover occludin takes part in the differentiation of ECs and signal pathways 
(Cardoso, Brites et al. 2010). Nevertheless, experiments with knockout mice showing 
that a lack of occludin can be compensated by other junctional proteins and the 
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functions and properties of the BBB are retained (Hawkins, O'Kane et al. 2006; 
Zlokovic 2008). 
 Adherens junctions, located below the TJ, are of great importance for the 
formation of TJ by providing structural support and holding cells together (Abbott, 
Patabendige et al. 2010; Cardoso, Brites et al. 2010). Cadherin, a Ca2+ dependent 
tansmembrane protein is linked to a protein of the catenin family (Cardoso, Brites et 
al. 2010). To date four catenins, alpha, beta, delta and gamma are known. Their 
main purpose is the connection of the cadherin complex to the actin filaments on the 
surface of ECs, forming a bridge between two cells (Cardoso, Brites et al. 2010). 
  Junctional complexes have a dynamic structure and react to changes in 
conditions during health and pathology. Under certain conditions, junctional proteins 
can disintegrate and reassemble in order to modulate the permeability of the BBB. 
Several kinases, such as mitogen-activated protein kinases, are involved in this 
process (Cardoso, Brites et al. 2010). The connection between protein 
phosphorylation and changes in the structure of TJ was confirmed by observations of 
the scaffolding protein ZO-1. The degree of phosphorylated ZO-1 was much higher in 
low resistance cells than in those with a high resistance to ion movement 
(Stevenson, Anderson et al. 1989). Furthermore, second messenger Ca2+ can also 
modulate the tightness of the BBB. Transmembrane protein cadherin is Ca2+-
dependent and the structure of AJs is broken at low concentrations of Ca2+, leading 
to hyperpermeability of the BBB (Cardoso, Brites et al. 2010). 
 
 Transports across the BBB 1.2.5
The properties and functions of the BBB hinder a number of compounds and 
essential nutrients from entering the CNS freely (Cardoso, Brites et al. 2010). 
Moreover, a number of different factors keep molecules from entering the CNS, such 
as a high polar surface and a molecule weight above 450 kDa. In addition, molecules 
with more than 6 hydrogen acceptors are limited in the passive transport across the 
BBB, because their movement into the lipid of the cell membrane requires a lot of 
energy. Therefore many different transport mechanisms, depending on properties 
and size of the compounds, exist to transfer these molecules across the BBB, as 
shown in Fig. 4 (Abbott, Patabendige et al. 2010). Small molecules can use the 
paracellular pathway to cross the BBB, charged and polar molecules have to be 
transported via the transcellular pathway (Petty and Lo 2002). 
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Figure 4 Pathways across the BBB (taken from Abbott, Ronnback et al. (2006). Further explanation in the text. 
Small, lipid-soluble and unipolar molecules, including ethanol, cross the BBB 
by passive diffusion. Blood gases, oxygen and carbon dioxide, move down their 
concentration gradients by diffusion, blood-flow dependent. The supply of gases is 
sufficient as long as physiological blood-flow is warranted (Abbott, Patabendige et al. 
2010). 
Solute carries, located in ECs of the BBB, facilitate the transport of polar 
compounds, such as glucose or amino acids to the CNS. Furthermore, small 
peptides, free fatty acids, organic anions and cations are transported by solute 
carriers (Abbott, Patabendige et al. 2010). Depending on the direction of the 
transport – from blood to brain or from brain to blood – solute carriers are inserted 
into either luminal, abluminal or both membranes of ECs (Abbott 2002; Bernacki, 
Dobrowolska et al. 2008). Glucose transporter-1 (GLUT-1) ensures sufficient supply 
of glucose, the main energy source of the CNS (Persidsky, Ramirez et al. 2006). This 
solute carrier is inserted into both ECs membranes, with more GLUT-1 molecules in 
the abluminal membrane. This uneven distribution prevents the risk of glucose-
accumulation at levels higher than those in the blood (Cardoso, Brites et al. 2010). 
Beside supplying the CNS with essential nutrients through soluble carriers, 
specific transporters in the BBB protect the brain from toxic and noxious substances 
by pumping them out of the brain compartment (Abbott, Patabendige et al. 2010). 
ATP-binding cassette transporters (ABC-transporters) are a superfamily of proteins 
with 48 members, divided into 7 sub-families (Dean, Rzhetsky et al. 2001). The most 
studied ABC-transporters for humans are P-glycoprotein (Pgp, Multidrug Resistance 
Protein, ABCB1), the Multidrug Resistance-associated Proteins (MRPs, ABCC1, 2, 4 
and 5) and Breast Cancer Resistance Protein (BRCP, ABCG2). In order to efflux 
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compounds actively out of the CNS, ABC-transporters are ATP-dependent (Abbott, 
Patabendige et al. 2010). The substrates for ABC-transporters are lipid-soluble 
compounds, such as neurotoxic molecules, whose removal protects the functions of 
the brain. Moreover, many drugs can be actively effluxed out of the brain, so 
increasing the lipid solubility of a drug does not guarantee penetration into the brain 
(Dauchy, Dutheil et al. 2008; Abbott, Patabendige et al. 2010). 
Macromolecules, such as proteins or peptides cross the BBB via endocytotic 
mechanisms. The transcytosis can be receptor-mediated (RMT) or absorptive-
mediated (AMT). In RMT ligands (e.g. Fe-transferrin) have to bind specific receptors 
(Transferrin) on the surface of ECs and a caveolus is formed. This vesicle crosses 
the cytoplasma of the endothelia and the internalised ligand is released at the other 
side (Abbott, Patabendige et al. 2010). In the AMT mechanism the protein has to be 
in the cationic form (cationised albumin) to merge with the binding sides on the 
surface and start the endocytosis followed by transcytosis and finally exocytosis 
(Sauer, Dunay et al. 2005). Both mechanisms ensure that macromolecules can cross 
the BBB intact (Abbott, Patabendige et al. 2010). 
 
  Blood-brain barrier in pathology 1.2.6
 Dysfunctions of the BBB are a part of several CNS pathologies, such as 
Parkinson’s disease, Alzheimer’s disease, epilepsy, multiple sclerosis, glaucoma and 
brain tumours (Abbott, Patabendige et al. 2010). The degree of the dysfunction 
differs and can even lead to total breakdown of the protective barrier function (Forster 
2008). When transport mechanisms become ineffective, toxic or noxious compounds 
can reach the brain, accumulating and causing damage. Moreover the supply of the 
brain with essential nutrients may become insufficient. Changes of BBB functions 
and compositions accelerate the progress of the CNS diseases, although it is 
unknown whether BBB dysfunctions play a role in the onset of the diseases (Abbott, 
Patabendige et al. 2010).    
 
1.3 BBB – study approaches 
The increasing number of neurodegenerative diseases, including PD and AD 
along with the pathological changes of the CNS led to a high interest in the BBB 
(Mensch, Oyarzabal et al. 2009). Moreover the BBB prevents > 98% of drugs from 
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entering the brain and BBB models are used to investigate properties of the BBB as 
well as transport mechanisms and test the ability of compounds to cross the BBB 
(Tosi, Costantino et al. 2008). There are different approaches to study the BBB – in 
vivo, ex vivo, in vitro and in silico – with every system having its advantages and 
disadvantages (Cardoso, Brites et al. 2010). 
 
 In vivo 1.3.1
The in vivo system provides the most reliable reference information for testing 
and validating other models (Pardridge 1999). This experimental system allows 
analysis of the whole brain and its biological processes (Cardoso, Brites et al. 2010). 
In vivo methods can be classified into invasive and non-invasive techniques and are 
used to investigate brain metabolism, transport mechanisms, neurological disease 
progression, drug biodistribution and BBB disruption (Mensch, Oyarzabal et al. 2009; 
Cardoso, Brites et al. 2010). In vivo experiments are mainly performed on brains of 
murines and primates using techniques, such as in vivo intravenous administration 
and in situ brain perfusion (Mensch, Oyarzabal et al. 2009; Cardoso, Brites et al. 
2010). Different knockout animals for BBB proteins have been used to determine 
permeability properties and study TJ functions (Furuse 2009). However, in needs to 
be taken into account that results from animal brains cannot be directly translated to 
humans (Cardoso, Brites et al. 2010). Moreover, experiments on living animals 
require expensive equipment and a large number of animals (Cohen-Kashi Malina, 
Cooper et al. 2009; Cardoso, Brites et al. 2010).  
 
 Ex vivo 1.3.2
 Ex vivo studies are performed on living tissue in a highly controlled 
environment (Cardoso, Brites et al. 2010). Tissue from brain specific regions is easily 
obtained and in contrast to in vivo models, more invasive studies can be performed, 
such as immunocytochemical procedures or fluorescent nuclear staining (Lossi, 
Alasia et al. 2009; Cardoso, Brites et al. 2010). Investigation of whole organs or 
systems is possible with ex vivo experimental systems providing information on 
neurological diseases, infectious diseases, neurovascular homeostasis and hypoxia. 
Furthermore, post-mortem tissue can be used to study TJ, basement membrane 
assembly along the evaluation of brain capillary permeability and expression of efflux 
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proteins. Limitations of the ex vivo models include the artificial environment and the 
rarity of human living samples. Moreover ex vivo experiments allow only short-term 
experiences (Cardoso, Brites et al. 2010). 
 
 In vitro 1.3.3
 The in vitro experimental system is a simplified model of the in vivo one 
(Cecchelli, Berezowski et al. 2007). In vitro models should be reproducible and mimic 
as closely as possible the in vivo barrier (Gumbleton and Audus 2001). In vitro 
models consist mainly of EC, since they are considered to be the anatomic basis of 
the BBB (Cardoso, Brites et al. 2010). To date several in vitro models are available to 
study BBB permeability and properties despite being difficult to reproduce and are 
time-consuming (Abbott 2002; Aschner, Fitsanakis et al. 2006). Many species are 
used for in vitro studies, including brain tissue from rodents, porcine and bovine 
(Cardoso, Brites et al. 2010).  
 The easiest way to mimic the BBB are cell lines, which are generated by 
immortalization of brain capillary endothelial cells (BCEC) using different 
immortalizing genes. Cell lines grow faster than primary cells and allow a large 
number of experiments in short time (Gumbleton and Audus 2001). Fields of study 
include transport systems, inflammatory cascades and toxicity modulation (Cardoso, 
Brites et al. 2010). However, cell lines cannot be used for permeability experiments 
since they only possess leaky intercellular junctions and lack paracellular junctions 
(Gumbleton and Audus 2001).  
 Primary cultures of BCEC present a more challenging in vitro model to 
investigate the BBB (Smith, Omidi et al. 2007). The monolayer of BCEC is grown on 
a microporous membrane filter culture insert, as shown in Fig.5A (Cohen-Kashi 
Malina, Cooper et al. 2009). Due to the limited availability of human brain tissue, 
bovine and porcine tissues are mainly used (Cecchelli, Berezowski et al. 2007). It is 
difficult to obtain pure EC, since all components of the NVU are very close together 
and it is intricate to remove all cells that envelop the EC. Moreover this model does 
not take the microenvironment into account (Calabria, Weidenfeller et al. 2006). 
Primary cultures are used for studies of neuroinflammation and disease processes as 
well as CNS drug delivery (Cardoso, Brites et al. 2010).  
 A more complex in vitro model are co-cultures, which take the importance of 
astrocytes into account (Cecchelli, Berezowski et al. 2007). Experiments showed that 
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astrocytes play a crucial role in the development of TJ. Moreover, co-cultures make it 
possible to investigate interactions between EC and other components of the NVU 
(Abbott, Ronnback et al. 2006). BCEC are co-cultured mainly with glial cells from rat 
brain and can be used to study BBB permeability (Cardoso, Brites et al. 2010). Due 
to the similar vascular physiology of the porcine and the human brain, porcine co-
culture models are suitable for studying the BBB. The co-culture experimental system 
can be either a non-contact co-culture with the glial cells seeded at the bottom of the 
Transwell (Fig. 5B) or a contact co-culture where the porcine brain endothelial cells 
(PBEC) are grown on the upper side of the Transwell membrane and the glial cells 
seeded on the underside of the filter membrane (Fig.5C). Contact co-culture models 
achieved the highest TEER measurements and display the closest anatomical 
features to the in vivo situation (Cohen-Kashi Malina, Cooper et al. 2009). 
 
Figure 5 Schematic drawings of three in vitro BBB culture systems (taken from Cohen-Kashi Malina, Cooper et al. 
(2009). 
 
 In silico 1.3.4
 In silico prediction methods are cheaper and less time-consuming than the in 
vivo and in vitro experimental systems, because large numbers of compounds can be 
screened rapidly (Mensch, Oyarzabal et al. 2009). Experimental data from in vivo 
methods provides the base for the computational models and algorithms (Cardoso, 
Brites et al. 2010). In silico methods are used to predict the ability of drugs to enter 
the brain (Mensch, Oyarzabal et al. 2009). Computer programmes, such as pCEL-X 
of pION can be used to model the various factors controlling transport of drug-like 
molecules across membranes in permeability measurements (Avdeef and Tsinman). 
Moreover transporters properties and protein activity can be predicted as well as 
toxicity evaluation (Cardoso, Brites et al. 2010). In has to be considered that in silico 
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methods are based on prediction models, use only total concentrations for modelling 
and cannot include the whole complexity and interactions of the BBB (Cardoso, 
Brites et al. 2010).  
 
 Transendothelial electric resistance – Indicator for BBB tightness 1.3.5
There are many indicators of BBB properties. Transendothelial electric resistance 
(TEER) has been considered to be the most accurate measurement of BBB tightness 
and barrier function (Cardoso, Brites et al. 2010). It is a useful indicator of 
paracellular ion flux as it reflects the impedance to the passage of small ions through 
a physiological barrier (Cohen-Kashi Malina, Cooper et al. 2009). There are plenty 
methods to measure TEER, which is 
expressed in Ω* cm2. The simplest method 
requires a voltohmmeter coupled to a pair of 
electrodes (Fig.6), which is accessible to 
most laboratories. Other systems (e.g. 
Electrical Cell-substrate Impedance Sensing 
(ECIS)) require more sophisticated 
equipment, which is connected to a 
computer for continuous measurement of 
TEER (Cardoso, Brites et al. 2010). A high 
quality in vitro model should attain high TEER measurement. Overall, average TEER 
values of monocultures are around 100 Ω* cm2. Using contact co-culture TEER 
values can be increased up to 1650 Ω* cm2 (Cohen-Kashi Malina, Cooper et al. 
2009).  
 
  
Figure 6 Schematic representation of the 
transendothelial electrical resistance measurement 
with electrodes (taken from Cardoso, Brites et al. 
(2010). 
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2 Aim of the project 
 
The aim of my four month project at King’s College London (KCL) was to gain more 
knowledge in organic chemistry and the synthesis of iron chelators aimed towards 
the treatment of Parkinson disease.  
One objective was to synthesis an iron chelator, which is 
coupled with a sugar molecule (Formula 4), since a sugar 
should enhance the chelators ability to enter the brain, which is 
the major target area for chelator therapies in Parkinson 
disease. Ideally, it was also aimed to assess whether the iron 
chelator was capable of entering the brain by determining 
whether it could cross the blood-brain barrier (BBB), which is a 
both a physical and metabolic barrier that exists between the 
blood and brain parenchyma that is known to restrict drug entry 
to the brain . 
The synthesis and biological studies of the iron chelators are part of a 
collaborating project between the Pharmacology and Therapeutics and Chemical 
Biology research groups of the KCL. Professor Robert C. Hider and his PhD student 
Ferdinand C. Fuchs were advising and helping me during the synthetic process of my 
project. Moreover I got an insight on the wide field of the BBB and in vitro 
experimental systems, during my work in the research group of Dr Jane Preston. 
 In order to test the synthesized iron chelator for its ability to cross the BBB, 
two different co-culture experimental systems were investigated for suitability. Four 
hydroxypyridin-4-one (HPO) derivatives with known properties were used to compare 
a contact co-culture with a non-contact co-culture experimental system, under the 
guidance of PhD student Ana Georgian. 
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Formula 4 Structure of the 
desired iron chelator 
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3 Materials and methods 
 
3.1 Materials 
 
 Instrumental details and equipment  3.1.1
 Nuclear magnetic resonance   3.1.1.1
Nuclear magnetic resonance (NMR) spectra were recorded using a Bruker 400 (400 
MHz) NMR spectrometer. Chemical shifts (δ) are reported in ppm downfield from the 
internal standard tetramethylsilane (Me4Si, δ=0). The notations s (singlet), d 
(doublet), t (triplet), q (quartet) and m (multiplet) were used to describe the resonance 
patterns. NMR samples were prepared by dissolving ~10mg of the compound in 0.5 
mL deuterated solvent. Data from the spectrometer was analysed using the software 
MestReNova (Mnova). 
 Melting points 3.1.1.2
An Electrothermal IA 9100 Melting Point Apparatus was used to determine the 
melting points. 
 Chromatography 3.1.1.3
Aluminum plates coated with silica gel 60 F254 from Merck were used for thin layer 
chromatography. When column chromatography was applied, silica gel 40-63 µm, 
technical grade from Sigma-Aldrich was used. 
 Mass spectrometry 3.1.1.4
A ThermoFinnigan LCQ Deca XP (electro-spray ionization, ESI) spectrometer was 
used for mass spectrometry. The procedure was carried out by the Centre of 
Excellence for Mass Spectrometry (CEMS-Waterloo) at the Waterloo campus of the 
King’s College London. The sample was prepared by dissolving 1 mg of the 
compound in 1 mL of MeOH. 
 High pressure liquid chromatography  3.1.1.5
High pressure liquid chromatography (HPLC) was conducted on a Waters system 
with a 717plus Autosampler, a 2996 Photodiode Array Detector, a 600s Controller 
and a 626 pump was used for HPLC, all purchased from Waters. The column used 
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was a reversed phase polymer column, PLRP-S, 300 Å, 8µm, 15 cm obtained from 
Waters. 
 
 Chemicals 3.1.1.6
All reagents and solvents were purchased from Sigma-Aldrich, Alfa-Aesar, Fisher 
Scientific, Fluka and Acros Organics, unless stated otherwise. The chemicals were in 
reagent or analytical grade and used without further purification.  
 Cells 3.1.1.7
The cells used to perform the experiments were provided by PhD student Ana 
Georgian from King’s College London. 
 Hydroxypyridinones (HPOs) 3.1.1.8
CP20 (deferipron), YMF-25, YMF-24 and YMF-16 (Formula 5) were used in this 
study. Deferipron was used as a control, because of its known ability to cross the 
BBB and was purchased from Sigma-Aldrich. The others HPOs, YMF-25, YMF-24 
and YMF-16 were already tested for their ability to cross the BBB in an in vivo 
system. In order to compare the in vivo and in vitro model the same HPOs were 
used. YMF-25, YMF-24 and YMF-16 were provided by Post-Doc Yongmin Ma from 
King’s College London. 
N
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Formula 5 Structures of the tested HPO-derivatives 
 
 
29 
 
3.2 Methods 
 Cell culture 3.2.1
The porcine brain endothelial cells (PBECs) were grown in co-culture with rat C6 
glioblastoma cells in 12-well 0.4µm pore, polycarbonate Transwells (Costar) (Figure 
7). In order to evaluate two systems, the cells were grown in non-contact co-culture 
as well as in contact co-culture; with PBECs grown on the top-side of the transwell, 
with C6 cells either on the bottom of the chamber below or on the underside of the 
Transwell-filter itself, respectively.  
 
Figure 7 12mm Transwell with 0.4µm pore polycarbonate membrane insert (taken from sigmaaldrich.com) 
 
PBECs were grown in DMEM (Dulbecco's Modified Eagle's Medium - low glucose) 
additionally containing 10% plasma derived bovine serum (First Link UK), 125µg/ml 
heparin, 2mM L-glutamine 100 U/ml Penicillin, 100µg/ml Streptomycin for 6 days at 
37ºC (5% CO2). For the first 3 days, media also included 4µg/ml puromycin (an 
endothelial cell selection toxin). On day 6, cells were passaged. PBECs were 
trypsinised and pelleted before being resuspended in fresh media and plated into the 
transwell filter (that had been precoated with collagen and fibronectin) at a density of 
1 x 105 cell/cm2. For non-contact co-culture, filters were then moved to 12-well plates 
already containing 100% confluent C6 cells. C6s (p132) were grown in DMEM (high 
glucose) with 10% foetal calf serum 100 U/ml Penicillin, 100µg/ml Streptomycin. C6 
were defrosted directly to plates at a density of 1 x 105 cell/cm2 and grew to 
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confluence after 2 days in culture. The media was changed after these 2 days, which 
was one day prior to the passaging of the PBECs. 
Alternatively, for contact co-culture, C6s were defrosted to the underside of the 
Transwell filter (precoated with collagen and fibronectin) and allowed to attach for 30 
minutes, then the transwell filters were placed in 12 well plates with C6 media, where 
C6 media was also added to the top-side of the filter to prevent coating from drying. 
These C6-filters were placed at 37ºC (5% CO2) for 1 day before PBECs were seeded 
into the top of the filter (after the astrocyte media had been removed). 
The PBECs were left in co-culture with the C6s for 3 days, before the media was 
changed to serum free media (DMEM-low glucose, 550nM hydrocortisone, 125µg/ml 
heparin, 2mM L-glutamine 100 U/ml Penicillin, 100µg/ml Streptomycin, with 250µM 
CPT-cAMP, 17.5µM RO-20-1724 (Calbiochem). 
TEER measurements were taken with STX100 probe, and EVOM to determine 
the tightness of the endothelial cells’ TJs, 24 hours after serum-free media was 
added. 
1.1.1 Permeability assay 
Permeability assays were conducted in assay buffer consisting of Hank’s Buffered 
Salt Solution (HBSS), 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) and 0.1% (v/v) bovine serum albumin (BSA), which was adjusted to 
pH 7.4. Solutions of the HPOs (800 µM in assay buffer containing 7.5 µg/mL sodium 
fluorescein) were also used. The solutions were heated up to 37°C and kept in the 
dark, since NaF is light sensitive. The media was removed from the Transwells 
containing the endothelial cells and the filters were moved to a new 12-well plate, 
where the bottom chamber (basolateral side) already contained 1.5 mL of the warm 
assay buffer. 500µL of the HPO solutions were added to the top chamber (apical 
side) of the filter insert and shaken at 200 rpm in an orbital shaker at 37°C and in the 
dark. After 60 minutes the filter inserts were transferred into a new 12-well plate in 
order to take prevent any transport into the bottom chamber. Then the whole volume 
of both chambers was taken into Eppendorf tubes® and frozen until HPLC analysis.  
The filter inserts were washed with phosphate-buffered saline (PBS) (3x) and then 
lysed with deionized H2O as detailed below.  
31 
 
1.1.2 Sodium fluorescein – paracellular marker 
Besides TEER measurement, the paracellular marker sodium fluorescein was used 
to determine the tightness of the junctions formed between the PBEC. The dye 
sodium fluorescein is not able to penetrate into endothelial cells; therefore its only 
way from the apical to the basolateral side is the paracellular route. Measuring the 
amount of NaF in the basolateral chamber is an indicator of the tightness of the tight 
junctions. 
 
Figure 8  - 96 well plate (taken from phenixresearch.com) 
 In order to determine the concentration of sodium fluorescein, a standard 
curve with different concentrations had to be generated. 100µL samples of the 
800µM HPO solutions were pipetted into a black 96-well plate (Figure 8) at different 
concentrations (100%, 25%, 5%, 1%, 0.20% and 0.05%). Moreover samples from 
each apical and basolateral chamber were pipetted into the plate, as well as the 
assay buffer as a blank. Sodium fluorescein is light sensitive; hence the plate had to 
be covered in foil to obtain accurate results. Fluorescence was measured at an 
absorption maximum of 494 nm and emission maximum of 521 nm, to generate a 
concentration curve of sodium fluorescein and determine the amount of the 
paracellular marker in the samples. These results were used to correct the HPO 
concentrations obtained from the HPLC-data. The measurements of the sodium 
fluorescein transfer were used to determine the percentage of HPO transfer via the 
paracellular route and subtracted from the overall transfer, which was measured by 
HPLC. 
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 Protein assay 3.2.2
In order to determine the intracellular accumulation of the HPOs, a protein assay was 
performed. After the filters had been washed with PBS (3x) and the inserts 
transferred into a new 12-well plate, 500µL water was added to each well in order to 
lyse the cells. The plate was stored at 37°C for 45 minutes. Then a cell scraper was 
used to scrape off the cells and the volume was pipetted into Eppendorf tubes®. Then 
TCA was added to the samples in order to precipitate any protein. The tubes were 
incubated at 4°C for 10 minutes and protein was peletted by centrifugation in 
microfuge at 10,000 x g for 5 minutes. The supernatant was then collected for HPLC 
analysis to determine the amount of HPO maintained intracellularly within the cells.  
 HPLC system 3.2.3
A gradient ion-pair HPLC method was used to analyse the HPOs in this study. The 
HPLC system consisted of an autosampler, a controller, a pump, a photodiode array 
detector and a reversed phase polymer column. The buffer and acetonitrile were 
degassed. A linear gradient of 2-35% of acetonitrile over 20 minutes was followed by 
a post run period of 5 minutes using 2% acetonitrile and 98% buffer. The buffer (1-
heptanesulfonic acid (sodium salt), 5mM in HPLC water) was adjusted to pH 2 using 
HCl. The injection volume was set to 100 µL. The flow rate was 1 mL/min and the 
compounds were monitored at 280 nm (Liu, Liu et al. 1999). The HPLC 
chromatograms were produced and analysed by using Millenium 32 software. 
 Statistical analysis 3.2.4
Statistical analysis was performed using GraphPad Prism software.  
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4 Synthetic schemes 
 
 
4.1 Synthesis of 2-methyl-3-benzyloxypyran-4(1H)-one 
 
O
O
OH Br
NaOH
O
O
O
CH3CH3
MW= 126,11 MW= 216,23
 
Scheme 1 Synthesis of 2-methyl-3-benzyloxypyran-4(1H)-one 
 
The starting material for the synthesis of the desired iron chelator was 2-methyl-
3hyrdoxy-4H-pyran-4-one (maltol), as shown in Scheme 1. The initial step was the 
protection of the hydroxyl group of maltol by benzylation. Applying the Williamson 
ether synthesis method, the starting material was treated with sodium hydroxide to 
generate the nucleophilic alcoxide. Then the alkyl halide benzyl bromide was added 
dropwise and the mixture refluxed overnight. Thus the nucleophilic alcoxide could 
attack the electrophilic carbon atom of the benzyl bromide and the desired benzyl 
ether was formed via an SN2 mechanism. After removal of the solvent under reduced 
pressure, the residue was dissolved in dichloromethane and washed with 5% 
aqueous sodium hydroxide followed by water. The organic layer was dried, filtered 
and rotary evaporated. Re-crystallization from diethyl ether afforded crystals in an 
acceptable yield, after the solution was allowed to stand in the fridge overnight.  
 The presence of the protective benzyl group was proved by the results from 
the 1H – nuclear magnetic resonance (1H - NMR) investigation. Deuterated methanol 
(MeOD) was used to dissolve the crystals for the 1H – NMR spectra. The hydrogen 
atoms from the CH2-group of the benzyl group appeared as a singlet at a chemical 
shift of 5.08 parts per million (ppm) whereas the aromatic hydrogen atoms showed a 
multiplet at δ 7.33 – 7.41.  
 The detailed synthetic procedure is described in section 5.1. 
 
 
34 
 
4.2 Synthesis of 1-(2´-carboxyethyl)-2-methyl-3-(benzyloxy)-4(1H)-
pyridinone 
O CH3
OBn
O
H2N OH
O
N CH3
O
OHO
OBn
NaOH
MW= 216,23
MW= 287,31
 
Scheme 2 Synthesis of 1-(2´-carboxyethyl)-2-methyl-3-(benzyloxy)-4(1H)-pyridinone 
The previously prepared benzyl-protected maltol can be converted into the 4-
pyridinone-derivative through an amine insertion reaction. The reaction starts with an 
aza-Michael-addition at the alpha, beta unsaturated ketone. The nucleophilic primary 
amine targets the oxygen in the 4-pyrone, the ring is hence opened and a molecule 
of water is eliminated. Thereafter, the ring closes again and the desired 4-pyridinone 
is generated.(Elkaschef 1960) 
   To convert the 4-pyrone into the desired 4-pyridone, β-alanine (3-
aminopropionic acid) was added to the starting material. The pH was adjusted to 13 
with NaOH and the mixture refluxed for 18 hours. Then the solution was reduced in 
volume and the pH acidified to 4, which led to a fluffy precipitation. This fluffy 
precipitate was extracted from the aqueous phase into DCM and the organic layer 
was filtered to yield a yellow powder. The powder was dissolved in the smallest 
possible amount of ethanol and then diethyl ether was added dropwise until the 
appearance of a slight cloudiness. The flask was stored at 4° C overnight to gain an 
acceptable yield of a slightly yellow powder.  
 The structure was investigated by 1H-NMR and the four protons of the 
carboxyethyl-moiety were observed at δ 2.58-2.61 and 4.13-4.16 ppm. The 
carboxylic proton could not be seen, because it dissociated in the solvent, MeOD. 
The protons of the pyridinone-derivative were found at chemical shifts as follows: δ 
2.10 (3H, s, CH3), 4.96 (2H, s, CH2Ph), 6.36-6.38 (1H, d, 5-H), 7.21-7.30 (5H, m, 
CH2Ph), 7.65-7.67 (1H, d, 6-H). 
 The detailed synthetic procedure is described in section 5.2. 
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4.3 Synthesis of 1-[2´-[(succinimidyloxy)carbonyl]ethyl)-2-methyl-3-
benzyloxy)-4(1H)-pyridinone 
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Scheme 3 Synthesis of 1-[2´-[(succinimidyloxy)carbonyl]ethyl)-2-methyl-3-benzyloxy)-4(1H)-pyridinone 
 
Applying the Steglich esterification method, the carboxylic acid group is treated with a 
coupling reagent, dicyclohexylcarbodiimide (DCC), and N-hydroxysuccinimide (NHS). 
DCC reacts with the starting material and forms a highly unstable active O-
acylisourea intermediate. The activated acid intermediate reacts with NHS forming 
the NHS-ester. (Neises and Steglich 1978; Hermanson 2008) (Neises and Steglich 
1978; Hermanson 2008) (Neises and Steglich 1978; Hermanson 2008) (Neises and 
Steglich 1978; Hermanson 2008) (Neises and Steglich 1978; Hermanson 2008) 
(Neises and Steglich 1978; Hermanson 2008) [2]  
 In order to generate the NHS-ester, the starting material was dissolved in dry 
DMF. DCC and NHS, also dissolved in DMF, were added and the solution stirred at 
room temperature for 18 hours. The mixture was filtered to remove dicyclohexylurea 
(DCU), a hardly soluble by-product and concentrated under reduced pressure to give 
a white solid. The product was stored in a desiccator to prevent hydrolysis of the 
NHS-ester. 
 1H-NMR – investigation proved the presence of the additional four protons of 
the NHS-ester-moiety. The protons appeared as a singlet at a chemical shift of 2.74 
ppm. 
 
 The detailed synthetic procedure is described in section 5.3.    
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4.4 Synthesis of 1,3,4,6-tetra-O-acetyl-β-D-glucosamine hydrochloride 
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Scheme 4 Synthesis of 1,3,4,6-tetra-O-acetyl-β-D-glucosamine hydrochloride 
 
For the synthesis of the desired iron chelator the glucosamine had to be selectively 
protected. First the amino group of the glucosamine is treated with anisaldehyde, to 
form the protective enamine, before acetylaction. Acetic anhydride and pyridine were 
added to convert the hydroxyl groups into acetic acid esters. In the last step, the p-
methoxybenzylidene group was removed with aqueous HCl to afford the desired 
1,3,4,6-tetra-O-acetyl-β-D-glucosamine hydrochloride.  
 Glucosamine hydrochloride was dissolved in NaOH and treated with p-
anisaldehyde. After stirring the solution was stored at room temperature, which lead 
to the formation of a crystal mass. The flask was stored at 4°C overnight. The crystal 
mass was collected on a Büchner funnel and washed with cold water followed by 
ether to yield the p-methoxybenzylidene derivative.  
 Acetylation was performed under cooling by the addition of acetic anhydride 
and pyridine. The mixutre was stored at room temperature for 24 hours and then 
poured into ice-cold water. The precipitate was filtered off to yield the N-[p-
methoxybenzyliden]-tetraacetyl-d-glucosamine.  
 In order to remove the p-methoxybenzylidene group, the protected 
glucosamine was dissolved in acetone and heated until boiling. After the addition of 
aqueous HCl precipitation of the glucosamine hydrochloride was observed. After 
cooling, ether was added and flask stored at 4° C. The crystals were collected on a 
Büchner funnel and washed with cold ether. Re-crystallization from MeOH afforded 
the desired glucosamine derivative.  
  
1H-NMR investigation confirmed the structure of the sugar and all signals of 
the protons could be assigned. δ 5.95-5.97 (1H, d , 1-H), 5.45-5.50 (1H, m, 3-H), 
5.12-5.17 (1H, m, 4-H), 4.37-4.40 (1H, m, 6a-H), 4.20-4.24 (1H, m, 6b-H), 3.93 (1H, 
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s, 5-H), 3.71-3.76 (1H, m, 2-H), 2.10 (3H, s, CH3), 2.11 (3H, s, CH3), 2.15 (3H, s, 
CH3), 2.23 (3H, s, CH3). 
 The detailed synthetic procedure will be described in section 5.4. 
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4.5 Synthesis of N-(1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranos-2-
yl)-3-(3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H)-yl)propanamide 
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Scheme 5 Synthesis of N-(1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranos-2-yl)-3-(3-(benzyloxy)-2-methyl-4-
oxopyridin-1(4H)-yl)propanamide 
Scheme 5 demonstrates the synthesis of the desired compound, by forming an 
amide bond between the activated ester and a primary amine. 1,3,4,6-tetra-O-acetyl 
glucosamine cannot react with the carboxylic acid directly, because it is a weak 
nucleophile. Therefore the carboxylic acid had been converted into the active ester, 
which is more prone to react with nucleophiles. Under mild conditions the primary 
amine reacts with the NHS-ester to form a stable amide bond. N-hydroxysuccinimide 
is released and a molecule of water is eliminated.(Montalbetti and Falque 2005; 
Hermanson 2008)  
 The starting material, 1-[2´-[(succinimidyloxy)carbonyl]ethyl)-2-methyl-3-
benzyloxy)-4(1H)-pyridinone, was dissolved in DMF/water (9:1) and N-
methylmorpholine was added. 1,3,4,6-tetra-O-acetyl glucosamine was dissolved in 
DMF/water (9:1) and added dropwise. The solution was stirred at room temperature 
for 14 hours. Afterwards, the solution was poured into water and stirred for 30 
minutes. The mixture was filtered and the filtrate dried by rotary evaporation to give 
an off-white solid. In order to remove the by-products the residue was taken up in 
DCM and washed with aqueous acetic acid, followed by water and aqueous 
bicarbonate solution. The organic fractions were collected and dried over anhydrous 
Na2SO4. After the sodium sulfate had been filtered off, the filtrate was dried by rotary 
evaporation to yield a dark residue. 1H-NMR investigation confirmed the presence of 
the desired compound.  In addition to the peaks of the pyridinone-derivate the 
protons of the acetyl-groups appeared as four singlet peaks at the chemical shifts of 
2.00, 2.02, 2.07 and 2.13.  
 The detailed synthetic procedure is described in section 5.5. 
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4.6 Deprotection of N-(1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranos-
2-yl)-3-(3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H)-yl)propanamide 
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Scheme 6 Deprotection of N-(1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranos-2-yl)-3-(3-(benzyloxy)-2-methyl-4-
oxopyridin-1(4H)-yl)propanamide 
 
To generate the desired iron chelator the protective groups, benzyl ether and acetic 
acid ester, had to be eliminated. Deprotection of the benzyl ether was performed as a 
palladium-catalysed hydrogenation, delivering the phenol and toluene. The protected 
iron chelator was dissolved in EtOH (100 mL) and palladium (5% water, on calcium 
carbonate, dosed with lead) was added. Hydrogenation was carried out at 40 psi 
overnight. The reaction was completed within 24 hours. After the catalyst had been 
filtered off, the solvent was removed under reduced pressure to yield 200 mg of a 
hard film. The reaction was monitored by TLC (DCM / MeOH 9:1). 
 In order to remove the acetyl groups the residue was taken up in CHCl3. An 
aliquot was taken and the solvent, CHCl3, dried by rotary evaporation. The remaining 
solid was dissolved in DMSO and a 100 mM NaOD-solution was prepared using 
sodium metal and D2O. Deuterated solvent was used to monitor the process of the 
reaction directly by NMR-investigation. 1 mL of this solution was added to the flask 
and the sample was analysed by 1H-NMR at different points of time in order to 
investigate when the cleavage of the acetyl groups was completed. Measurements 
were carried out after 5, 40 and 100 minutes. Analysis of the NMR spectra showed 
that the reaction was very fast, because the signals of the acetyl groups were 
decreased after 5 minutes. There was no significant change between the spectra 
taken at later points of time. This confirms that a 100 mM NaOH-solution is sufficient 
to eliminate the acetic acid esters.    
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 These steps were repeated with the remaining residue. The content of the 
flask was dissolved in DMSO and a 100 mM NaOH solution was added. The flask 
was stored at room temperature for one hour. Then deionized water was added and 
the pH neutralized to 7 with aqueous HCl. After extraction into CHCl3, the organic 
layer was dried over Na2SO4 and filtered. The solvent was removed under reduced 
pressure to yield 14 mg of a white residue. 1H-NMR analysis showed lack of the 
desired product. The spectrum contained only peaks of the solvent (DMSO). 
Therefore, the aqueous phase was saturated with NaCl in order to reduce the 
solubility of the compound in water and placed in a separating funnel. Chloroform 
was added and the funnel shook several times over ten minutes. The organic layer 
was dried over Na2SO4, filtered and dried by rotary evaporation to yield a colourless 
film. NMR investigation showed again lack of the desired compound.  
  
 The conditions of the deprotection need to be investigated further. A possible 
way could be to remove the acetyl groups first. In this order the molecule stays more 
hydrophobic and it should be extracted more easily into CHCl3. Then the cleavage of 
the benzyl ether could be performed by hydrogenation.  
 Unfortunately, the protected iron chelator was used up and due to the limited 
time that was available for my project the deprotection could not be repeated.  
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5 Synthetic procedures 
 
 
5.1 Synthesis of 2-methyl-3-benzyloxypyran-4(1H)-one 
 
The procedure of this synthesis was taken from J. Med. Chem. 1993, 36, 2448 – 
2458: Synthesis, Physicochemical Properties, and Biological Evaluation of N-
substituted 2-Alkyl-3-hydroxy-4(1H)-pyridinones: Orally Active Iron Chelators with 
Clinical Potential(Gaeta, Molina-Holgado et al. 2011) 
 
Maltol (25.0011 g; 198.24 mmol) was dissolved in 250 mL MeOH in a two-neck round 
bottomed flask, equipped with a magnetic stirrer. A solution of NaOH (8.48 g) in 30 
mL water was added. Then benzyl bromide (25.3 mL; 212.4 mmol) was added 
dropwise through an addition funnel to the stirred solution. The bath temperature was 
adjusted to 70° Celsius and the mixture was refluxed overnight. During the night the 
colour of the clear solution turned to dark orange. On the next day the completion of 
the reaction was checked by TLC (hexane / ethyl acetate 1:1). The solvent (MeOH) 
was removed under reduced pressure. The residue was dissolved in 100 mL DCM 
and placed in a separating funnel. The solution was washed first with 5% sodium 
hydroxide (2x 100 mL) followed by water (2x 100 mL). The organic layer was dried 
over anhydrous sodium sulfate, filtered and the solvent removed under reduced 
pressure to yield an oil which solidified on cooling. Re-crystallization from diethyl 
ether afforded off-white crystals and the flask was stored at 4° C overnight. The next 
day the crystal mass was filtered and washed with cold diethyl ether to gain white 
crystals; yield: 50%. Melting point: 54-55° C. 1H-NMR (MeOD): δ 2.12 (3H, s, CH3), 
5.08 (2H, s, CH2Ph), 6.41-6.42 (1H, d, 5-H), 7.33-7.41 (5H, m, CH2Ph), 7.93-7.94 
(1H, d, 6-H).  
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5.2 Synthesis of 1-(2´-carboxyethyl)-2-methyl-3-(benzyloxy)-4(1H)-
pyridinone 
 
The procedure of this synthesis was taken from J. Med. Chem. 1993, 36, 2448 – 
2458: Synthesis, Physicochemical Properties, and Biological Evaluation of N-
substituted 2-Alkyl-3-hydroxy-4(1H)-pyridinones: Orally Active Iron Chelators with 
Clinical Potential(Gaeta, Molina-Holgado et al. 2011) 
 
To a solution of 2-methyl-3-(benzyloxy)-4(4H)-pyranone (5.4014 g; 25 mmol) in 
ethanol (63 mL) in a round bottomed flask containing a magnetic stirrer was added β-
alanine (2.6060 g; 30 mmol) dissolved in water (63 mL). 10 N sodium hydroxide 
solution was used to adjust the pH to 13. The mixture was refluxed overnight at a 
bath temperature of 100° C. After 18 hours of reflux the clear solution had turned 
dark orange. The reaction was monitored by TLC (ethyl acetate / acetic acid 9:1). 
The solution was reduced in volume and the pH adjusted to 4, using 5N HCl. The 
residue was extracted into DCM (3x 50 mL) and the organic layer dried over sodium 
sulfate. After the sodium sulfate was filtered off, the solvent was removed under 
reduced pressure to afford crystals. The residue was dissolved in the smallest 
possible amount of ethanol and then diethyl ether was added slowly until the 
appearance of a slightly cloudiness. The mixture was stored at 4° C overnight. The 
precipitate was filtered and washed with cold ether. Yellow crystals were obtained in 
50% yield. MP: 170-171° C. 1H-NMR (MeOD): δ 2.10 (3H, s, CH3), 2.58-2.62 (2H, m, 
N-CH2-CH2-), 4.13-4.17 (2H, m, N-CH2-CH2-), 4.96 (2H, s, CH2Ph), 6.36-6.38 (1H, d, 
5-H), 7.21-7.30 (5H, m, CH2Ph), 7.66-7.67 (1H, d, 6-H). 
 
 The reaction was repeated with the aim of increasing the yield. To a solution of 
2-methyl-3-(benzyloxy)-4(4H)-pyranone (10 g; 48 mmol) in ethanol (120 mL) was 
added β-alanine (5 g; 56 mmol) dissolved in water (120 mL). The pH was adjusted to 
13 with 10 N NaOH and the mixture refluxed for 18 hours. The reaction was 
monitored by TLC (EtOAc / acetic acid 9:1). The mixture was reduced in volume by 
rotary evaporation and the remaining solution was acidified with HCl to pH 4. A 
change in colour from clear to dark yellow and precipitation was observed. DCM was 
added to wash the aqueous phase (3x 100 mL). The precipitate was collected on a 
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Büchner funnel and dried over vacuum. 1H-NMR investigation of this yellow 
precipitate confirmed the structure and showed that the product was sufficiently pure 
for synthetic use. Yield was increased to 70%. MP: 170-171° C. 1H-NMR (MeOD): δ 
2.10 (3H, s, CH3), 2.58-2.61 (2H, m, N-CH2-CH2-), 4.13-4.16 (2H, m, N-CH2-CH2-), 
4.96 (2H, s, CH2Ph), 6.36-6.38 (1H, d, 5-H), 7.21-7.30 (5H, m, CH2Ph), 7.65-7.67 
(1H, d, 6-H). 13C-NMR (MeOD): δ 12.80 (CH3), 35.43 (N-CH2-CH2-), 50.90 (N-CH2-
CH2), 74.60 (CH2Ph), 117.17 (5-C), 129.39+129.45+130.29+138.41 (CH2Ph), 141.62 
(6-C), 145.34 (2-C), 147.02 (3-C), 173.51 (N-CH2-CH2-COOH), 174.70 (4-C). 
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5.3 Synthesis of 1-[2´-[(succinimidyloxy)carbonyl]ethyl)-2-methyl-3-
benzyloxy)-4(1H)-pyridinone 
 
The procedure of this synthesis was taken from J. Med. Chem. 1993, 36, 2448 – 
2458: Synthesis, Physicochemical Properties, and Biological Evaluation of N-
substituted 2-Alkyl-3-hydroxy-4(1H)-pyridinones: Orally Active Iron Chelators with 
Clinical Potential(Gaeta, Molina-Holgado et al. 2011) 
 
This section will describe different approaches to synthesize 1-[2´-
[(succinimidyloxy)carbonyl]ethyl)-2-methyl-3-benzyloxy)-4(1H)-pyridinone since some 
difficulties were experienced and the conditions of this reaction had to be more 
carefully defined.  
In the first attempt the 1-(2´-carboxyethyl)-2-methyl-3-(benzyloxy)-4(1H)-pyridinone 
(0.5752 g; 2 mmol) and NHS (0.2312 g; 2 mmol) were dissolved in DMF (20 mL). 
After the addition of DCC (0.4137 g; 2 mmol) the solution was stirred at room 
temperature for 18 hours. The reaction was monitored by TLC (EtOAc / ACN / MeOH 
2:2:1). The solution was filtered in order to remove DCU and the solvent was 
evaporated under reduced pressure to yield a light yellow solid. The residue was 
dissolved in the smallest possible amount of DCM followed by ether. After the 
addition of ether some crystals started to form immediately, so the flask was stored 
overnight at room temperature. On the next day the amount of crystals was very low 
and the flask contained some oily remains. The solvents (DCM / ether) were 
removed under reduced pressure in order to try the re-crystallization again. This time 
the flask was left in the fridge overnight, however the yield of the crystals remained 
low. The solid was separated from the oily phase and both samples were taken for 
1H-NMR investigation. The NMR-spectra showed lack of the desired compound. The 
signals of the chemical shifts could be assigned to the reactants.  
 In the second attempt two equivalents of DCC were used. The conditions and 
the amount of the other reactants were retained. The solution was stirred for 18 
hours and filtered. The reaction as monitored by TLC (EtOAC / ACN / MeOH 2:2:1). 
The solvent was removed under reduced pressure and DCM was added. 
Unfortunately, the mixture did not become clear, despite adding large amounts of 
DCM, so re-crystallization was impossible. By using a different mobile phase (CHCl3 / 
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MeOH 4:1) for the TLC the three highest spots could be separated enough for 
column chromatography. All fractions containing the desired spots were collected 
and the solvents removed by rotary evaporation. 1H-NMR investigation showed again 
presence of the reactants and absence of the desired product. Consequently, 
increasing the amount of the coupling reagent does not improve the reaction.  
 In the next approach anhydrous DMF was used, which had been distilled on 
the same day. In a three-neck-flask 2 mmol of 1-(2´-carboxyethyl)-2-methyl-3-
(benzyloxy)-4(1H)-pyridinone (0.57015 g) were put under vacuum followed by N2-flow 
for three times to get rid of all the air inside the flask. The other two necks of the flask 
were suba-sealed. Then dry DMF (12 mL) was added using a syringe to dissolve the 
pyridinone-derivative. The other reactants, DCC and NHS, were dissolved in DMF (3 
mL each), using separate flasks and also added to the three-neck-flask through a 
syringe. The solution was stirred at room temperature under constant N2-flow for 18 
hours. The presence of a white precipitate, DCU, indicated that some kind of reaction 
had occurred. This precipitate was filtered off and the solvent removed under 
reduced pressure. DCM was added to the residue in order to re-crystallize it.  The 
solid did not dissolve completely in DCM and an excess of ether was added which 
led to precipitation. The flask was stored at room temperature to gain more of the 
precipitate. The mixture was filtered by suction and the precipitate washed with cold 
ether and dried under vacuum. 1H-NMR investigation proved the presence of the 
desired compound, by showing the additional four protons of the NHS-ester-moiety at 
a chemical shift of 2.74 ppm.  
However, the NMR-spectrum contained some impurities, and so the sample 
was subjected to re-crystallization. 100 mg of the solid were dissolved in DCM (3 mL) 
and heated. This mixture was filtered and then an excess of ether was added to the 
filtrate. Some crystals formed and the flask was stored at 4° C. The mixture was 
filtered and the mother liquor was removed under reduced pressure to yield 20 mg of 
crystals. 1H-NMR investigation showed a spectrum with even more impurities. Maybe 
the product hydrolysed partly during the process of re-crystallization. This crude 
product was used for the next reaction. Yield: 77%. MP: 144 - 147° C. 1H-NMR 
(MeOD): δ 2.10 (3H, s, CH3), 2.74 (4H, s, N-C(=O)-CH2-CH2-C(=O)), 2.99-3.02 (2H, 
m, N-CH2-CH2-), 4.26-4.29 (2H, m, N-CH2-CH2-), 4.96 (2H, s, CH2Ph), 6.34-6.36 (1H, 
d, 5-H), 7.22-7.31 (5H, m, CH2Ph), 7.66-7.67 (1H, d, 6-H). 13C-NMR (MeOD): δ 12.77 
(CH3), 26.09 (N-C(=O)-CH2-CH2-C(=O)), 32.51 (N-CH2-CH2-), 49.92 (N-CH2-CH2), 
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74.63 (CH2Ph), 117.46 (5-C), 129.39+129.47+130.34+138.42 (CH2Ph), 141.63 (6-C), 
145.12 (2-C), 147.15 (3-C), 167.76 (N-CH2-CH2-COO-), 171.56 (N-C(=O)-CH2-CH2-
C(=O)), 175.16 (4-C) 
 
In order to investigate the conditions of this reaction further the reaction was 
performed without N2-flow. The reactants were dissolved in anhydrous DMF in three 
separate flasks, which had been washed with acetone, dried in an oven and then 
stored in a desiccator. 1-(2´-Carboxyethyl)-2-methyl-3-(benzyloxy)-4(1H)-pyridinone 
(0.9987 g) was dissolved in 20 mL DMF in a round bottomed flask and suba-sealed. 
NHS (0,426 g) and DCC (0.718 g) were dissolved in DMF (5 mL each) and added to 
the round bottomed flask using a syringe. The mixture was stirred at room 
temperature overnight and the flask additionally covered with parafilm. DCU 
precipitated and indicated that some kind of reaction did occur. The precipitate was 
collected on a Büchner funnel and the filtrate evaporated to yield a off-white solid. 
The residue was investigated by 1H-NMR spectroscopy. The NMR-spectrum shows 
the four protons of the NHS-ester, but again impurities of around 30%. The additional 
peaks could be assigned to 1-(2´-carboxyethyl)-2-methyl-3-(benzyloxy)-4(1H)-
pyridinone, starting material that did not react. Yield: 77 %. MP: 144 - 146° C. 1H-
NMR (DMSO): δ 2.23 (3H, s, CH3), 2.82 (4H, s, N-C(=O)-CH2-CH2-C(=O)), 3.189-
3.21 (2H, m, N-CH2-CH2-), 4.22-4.26 (2H, m, N-CH2-CH2-), 5.0 (2H, s, CH2Ph), 6.14-
6.15 (1H, d, 5-H), 7.31-7.43 (5H, m, CH2Ph), 7.66-7.67 (1H, d, 6-H).  
 
To gain an acceptable yield of the NHS-ester, the reaction does not have to be 
performed under N2-flow. The use of dry DMF is essential, because the active ester 
is labile to hydrolysis. Therefore anhydrous conditions are very important and the 
product should be stored in a desiccator in order to prevent it from decomposition.    
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5.4 Synthesis of 1,3,4,6-tetra-O-acetyl-β-D-glucosamine hydrochloride 
 
The procedure of the this synthesis was taken from Eur. J. of inorganic Chem. 1964, 
64, 978: Synthesen mit Glucosamin.(Bergmann and Zervas 1964) 
 
To synthesize the desired iron chelator a selectively protected glucosamine had to be 
prepared. Following the instructions of the paper, the glucosamine hydrochloride (10 
g) was dissolved in 1N NaOH (47 mL). Then p-anisaldehyde (5.7 mL) was added and 
the solution stirred well. When the flask was stored at room temperature crystals 
began to form and the flask was stored at 4° C overnight. The crystal mass was 
collected on a Büchner funnel and washed with ice-cold water followed by ether to 
yield 69% of the N-protected p-methoxybenzylidene derivative. The product was 
dried under vacuum. 
 In the next step a part of the N-protected sugar (5.0197 g) was dissolved with 
cooling in a mixture of acetic anhydride (15 mL) and dry pyridine (27 mL). The 
solution was stirred for 30 minutes and then the flask was stored at room 
temperature over 48 hours. Afterwards the mixture was poured into ice-cold water 
and the precipitate filtered off. The acetylated product was dried over vacuum to 
afford 70% of crystals.  
 In the last step the protected glucosamine is treated with HCl in order to 
remove the p-methoxybenzylidene group. The protected sugar (4.9996 g) was 
dissolved in the smallest possible amount of acetone and refluxed. Addition of 1 
equivalent of 5N HCl (2 mL) led to immediate precipitation of the hydrochloride 
derivative. After cooling, the solid was broken up and ether (5 mL) was added. The 
mixture was stirred for 30 minutes and then the flask was stored at 4° C overnight. 
The precipitate was filtered off and washed with ice-cold ether. The crystals were 
dried in a desiccator. White crystals were obtained in 90% yield. NMR investigation 
confirmed the structure of 1,3,4,6-tetra-O-acetyl-β-D-glucosamine hydrochloride. MP: 
> 230 °C: becomes dark without melting. 1H-NMR (D2O): δ 5.95-5.97 (1H, d , 1-H), 
5.45-5.50 (1H, m, 3-H), 5.12-5.17 (1H, m, 4-H), 4.37-4.40 (1H, m, 6a-H), 4.20-4.24 
(1H, m, 6b-H), 3.93 (1H, s, 5-H), 3.71-3.76 (1H, m, 2-H), 2.10 (3H, s, CH3), 2.11 (3H, 
s, CH3), 2.15 (3H, s, CH3), 2.23 (3H, s, CH3). 13C-NMR (D2O): δ 19.96 (O=C-CH3), 
20.0 (O=C-CH3), 20.13 (O=C-CH3), 52.37 (2-C), 61.38 (6-C), 67.97 (4-C), 71.05 (3-
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C), 72.07 (5-C), 90.60 (1-C), 171.21 (O=C-CH3), 172.66 (O=C-CH3), 172.99 (O=C-
CH3), 173.52 (O=C-CH3). 
 
 The preparation of 1,3,4,6-tetra-O-acetyl-β-D-glucosamine hydrochloride was 
repeated with benzaldehyde to gain more material for the following coupling reaction. 
To a solution of glucosamine hydrochloride (10 g) in 1N NaOH (47 mL) was added 
benzaldehyde (6 mL). The solution was stirred for 30 minutes and the flask stored at 
4° C overnight. In contrast to the reaction with p-anisaldehyde there was no 
precipitate. The solution was placed in a separating funnel and ethyl acetate (50 mL) 
was added. Precipitation of white flakes occurred immediately. The precipitate was 
collected on a Büchner funnel and dried over vacuum. 1H-NMR investigation proved 
presence of the N-protected glucosamine. Yield: 45%. 
 A part of the N-protected sugar (5.0048 g) was taken up in a mixture of acetic 
anhydride (15 mL) and dry pyridine (27 mL) under cooling. The solution was stirred 
for 30 minutes and then the flask was stored at room temperature over 48 hours. The 
mixture was poured into ice-cold water and the precipitate filtered by suction to yield 
57%. 
 The smallest possible amount of acetone was used to dissolve the acetylated 
intermediate (3.9994) and refluxed. After the addition of 1 equivalent of 5N HCl the 
solution solidified immediately. The mass was broken up after cooling. Diethyl ether 
was added (5 mL) and the solution stirred for 30 minutes. The flask was stored at 4° 
C overnight. The crystals were collected on a Büchner funnel and dried over vacuum 
to afford 68% of white crystals. 1H-NMR investigation confirmed the structure of 
1,3,4,6-tetra-O-acetyl-β-D-glucosamine hydrochloride. 1H-NMR (D2O): δ 5.94-5.96 
(1H, d , 1-H), 5.45-5.49 (1H, m, 3-H), 5.12-5.17 (1H, m, 4-H), 4.37-4.41 (1H, m, 6a-
H), 4.23-4.24 (1H, m, 6b-H), 4.20-4.21 (1H, s, 5-H), 3.71-3.75 (1H, m, 2-H), 2.10 (3H, 
s, CH3), 2.11 (3H, s, CH3), 2.15 (3H, s, CH3), 2.23 (3H, s, CH3). 13C-NMR (D2O): δ 
19.97 (O=C-CH3), 20.0 (O=C-CH3), 20.13 (O=C-CH3), 52.39 (2-C), 61.38 (6-C), 
67.98 (4-C), 71.11 (3-C), 72.07 (5-C), 90.67 (1-C), 171.23 (O=C-CH3), 172.67 (O=C-
CH3), 173.01 (O=C-CH3), 173.52 (O=C-CH3). 
 
 In summary, both aldehydes can be used to synthethize the desired 1,3,4,6-
tetra-O-acetyl-β-D-glucosamine hydrochloride in acceptable yield. Using p-
anisaldehyde the yield was 20% higher, however the NMR spectrum showed some 
49 
 
additional peaks. The peaks could be assigned to reactants, pyridine and p-
anisaldehyde. Re-crystallization from MeOH afforded the pure 1,3,4,6-tetra-O-acetyl-
β-D-glucosamine hydrochloride. The spectrum of the 2nd reaction was very clean with 
no additional peaks and showed that the product was sufficiently pure for synthetic 
use.  
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5.5 Synthesis of N-(1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranos-2-
yl)-3-(3-(benzyloxy)-2-methyl-4-oxopyridin-1(4H)-yl)propanamide 
 
The procedure of this synthesis was taken from Eur. J. Org. Chem. 2006, 2715 – 
2722: N-Carboxymethylated 6,7-Dimethoxy-4-trifluoromethylcarbostyrils as 
Fluorescence Markers for Amino Acids, Peptides, Amino Carbohydrates and Amino 
Polysaccharides.(Badgujar 2006) This article describes the formation of an amide 
bond between a similar active ester and glucosamine hydrochloride. According to the 
paper a high yield of the desired amide was achieved, therefore the synthesis N-
(1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranos-2-yl)-3-(3-(benzyloxy)-2-methyl-4-
oxopyridin-1(4H)-yl)propanamide was performed under the same conditions.  
 
Following the instructions of the above mentioned paper the active ester, 1-[2´-
[(succinimidyloxy)carbonyl]ethyl)-2-methyl-3-benzyloxy)-4(1H)-pyridinone (149.5 mg; 
0.39 mmol) was dissolved in DMF/water (9:1; 5.6 mL + 624 µL) and N-
methylmorpholine (43 µL; 0.39 mmol) was added. 1,3,4,6-Tetra-O-acetyl 
glucosamine hydrochloride (150 mg; 0.39 mmol), dissolved in DMF/water (9:1; 5.6 
mL + 624 µL) was added dropwise. The solution was stirred at room temperature 
overnight. The mixture was poured then into water (45 mL) and stirred for 30 
minutes. According to the paper the desired product should precipitate, but no such 
precipitate formed. The TLC plate of the solution showed additional spots to the 
starting materials, which indicated that a reaction had taken place. Bicarbonate was 
used to adjust the pH to 9 and the flask was stored at room temperature for 30 
minutes. After extraction into EtOAc (2x 60 mL) the organic layer was dried over 
Na2SO4. The solvent was removed under reduced pressure to give a white residue. 
Analysing a sample of this residue by 1H-NMR investigation demonstrated the 
absence of the desired product.  
In the next attempt 1,3,4,6-tetra-O-acetyl glucosamine hydrochloride was 
converted into the free base. The sugar (248 mg) was dissolved in water (50 mL) and 
N-methylmorpholine (71.5 µL) was added. The flask was stored for 10 minutes at 
room temperature. Then the solution was extracted into DCM (2x 25 mL), the organic 
fractions dried over Na2SO4. The active ester (286 mg) was taken up in DCM (10 mL) 
and filtered, to remove the undissolved residue. Both filtrates were combined and the 
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flask stored at room temperature for 24 hours. The reaction was monitored by TLC 
(EtOAc / ACN / MeOH 2:2:1). The solution was extracted into water (2x 50 mL) and 
the organic layer dried over Na2SO4 followed by filtration. The solvent was removed 
under reduced pressure to afford off-white crystals. Analysing a sample of this 
residue by MS showed the main peak at a mass-to-charge ratio (m/z) of 617.1, which 
confirmed the presence of the desired compound. NMR investigation showed 
characteristic peaks of the product. However, many peaks of uncoupled sugar were 
also present; thus the purification of this compound was necessary. Yield: 60 %. MP: 
86 - 92° C. MS (ESI) m/z: 617.1. 
 In an attempt to obtain a more homogenous product, the reaction was 
repeated under slightly different conditions. The active ester (330 mg) was taken up 
in DCM (10 mL) and filtered. The filtrate was kept for the reaction. Then the 
glucosamine hydrochloride (275 mg) was dissolved in water (50 mL) and N-
methylmorpholine (79 µL) was added in order to generate the free base of the sugar. 
After one minute the solution was extracted into DCM (2x 25 mL). The organic 
fraction was dried over Na2SO4 and filtered. Both filtrates were combined and the 
flask stored for three hours at room temperature. After extraction into water (2x 50 
mL), the organic layer was dried over Na2SO4. The solvent was removed under 
reduced pressure to give white crystals. Analysis of the 1H-NMR spectrum shows that 
the sample contains 45% of product but also 55% of uncoupled sugar. In order to 
purify the product DCM (15 mL) was added and the solution was washed with 
sodium acetate buffer (25 mM; adjusted to pH 4 with acetic acid; 2x 15 mL). 
Afterwards the organic phase was washed with water (1x 15 mL), dried over 
anhydrous sodium sulfate and reduced by rotary evaporation. Part of the residue was 
taken for 1H-NMR analysis, which demonstrated a 1:1 ratio of product: sugar. The 
extraction was repeated, but this time the pH of the sodium acetate buffer was set to 
3. After filtration and removal of the solvent the NMR-spectrum shows lack of the 
uncoupled sugar, thus confirming that extraction can be applied to purify the product. 
Yield: 10 %. 1H-NMR (DMSO): δ 1.88 (3H, s, OAc), 1.91 (3H, s, OAc), 1.97 (3H, s, 
OAc), 2.00 (3H, s, OAc), 2.19 (3H, s, CH3), 3.96 (1H, d, 2-H’’), 4.03 (1H, d, 5-H’’), 
4.05 (1H, d, 6b-H’’), 4.16 (1H, d, 6a-H’’), 4.86-4.91 (1H, t, 4-H’’), 4.99 (2H, s, CH2Ph), 
5.15-5.20 (1H, t, 3-H’’), 5.70 (1H, d, 1-H’’), 6.10-6.12 (1H, d, 6-H), 7.32-7.42 (5H, m, 
CH2Ph), 7.50-7.52 (1H, d, 5-H), 8.17-8.19 (1H, d, NH). 
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 In another attempt, 1-[2´-[(succinimidyloxy)carbonyl]ethyl)-2-methyl-3-
benzyloxy)-4(1H)-pyridinone (1.0276 g; 2.68 mmol) was dissolved in aqueous DMF 
(40 mL) and N-methylmorpholine was added (256 µL; 2.68 mmol). Then the 
glucosamine hydrochloride derivative (1.067g; 2.68 mmol) was dissolved in aqueous 
DMF (40 mL) and added dropwise through an addition funnel to the stirred solution. 
The solution was stirred at room temperature overnight. Afterwards the solution was 
poured into water (320 mL) and stirred for 30 minutes at room temperature. The 
mixture was filtered and the solvent removed under reduced pressure. The residue 
was taken up in DCM (100 mL) and washed with aqueous acetic acid (pH 5, 2x 50 
mL), water (1x 50 mL) followed by bicarbonate solution (pH 8, 2x 50 mL). The 
organic layer was dried over Na2SO4, filtered and dried by rotary evaporation to yield 
12% of a dark brown solid. NMR investigation confirmed the structure of the desired 
product. 1H-NMR (CDCl3): δ 1.96 (3H, s, CH3), 2.0 (3H, s, OAc), 2.02 (3H, s, OAc), 
2.07 (3H, s, OAc), 2.13 (3H, s, OAc), 2.49-2.50 (2H, m, N-CH2-CH2-), 3.74 (1H, m, 2-
H’’), 4.01 (1H, d, 5-H’’), 4.05-4.06 (2H, m, N-CH2-CH2-), 4.11 (1H, d, 6b-H’’), 4.25 
(1H, d, 6a-H’’), 5.01 (1H, m, 4-H’’), 5.12 (2H, s, CH2Ph), 5.38 (1H, t, 3-H’’), 5.89 (1H, 
d, 1-H’’), 6.27-6.19 (1H, d, 6-H), 7.31-7.39 (5H, m, CH2Ph), 7.51-7.53 (1H, d, 5-H), 
8.36-8.38 (1H, d, NH). 13C-NMR (CDCl3): δ 12.41 (CH3), 20.63 (O=C-CH3), 20.70 
(O=C-CH3), 20.74 (O=C-CH3), 20.91 (O=C-CH3), 36.35 (N-CH2-CH2-), 53.31 (2-C’’), 
61.60 (6-C’’), 68.19 (3-C’’), 72.25 (5-C’’), 72.67 (CH2Ph), 73.18 (4-C’’), 92.03 (1-C’’), 
116.37 (2-C), 116.70 (5-C), 128.28+ 128.45+ 128.96+ 129.0+ 137.08 (CH2Ph), 
138.85 (3-C), 145.87 (6-C), 169.10+ 169.45+ 169.61+ 170.32 (O=C-CH3), 170.70 (N-
CH2-CH2-CONH-), 172.93 (4-C).   
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6 Results 
 
 
6.1 HPLC of HPOs (CP20, YMF25, YMF24, YMF16) 
Before analysing samples of the BBB-experiment, samples of CP20 were run in 
deionized water to localize the peak and determine the quality and purity of the 
column. 100 µL of CP20 was injected at a concentration of 100 µM. 
 
Figure 9 CP20 HPLC 
100µl of 100µM CP20 from Sigma was analysed by HPLC 
 
The chromatogram of CP20 in deionized water (Figure 9) showed a 
symmetrical peak at a retention time (RT) of ~11 minutes, but also some small 
additional peaks, which did not interfere with the peak of CP20. These impurities 
could be particles of the purified water or artefacts on the column. 
Another sample of 100 µM CP20 was run, but this time CP20 was provided by 
Post-Doc Yongmin Ma (Figure 10). The chromatogram showed the main peak again 
at RT ~ 11 minutes and impurities of the purified water. 
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Figure 10 CP20 from Post-Doc Yongmin Ma 
100µl of 100µM CP20 made by Yongmin Ma was analysed by HPLC 
 
 
 
Therefore, CP20 from Sigma-Aldrich can be used for the experiments and for 
the calibration curve, since the impurities do not interfere with the RT of CP20 or with 
the RT of the other HPO-derivatives, YMF25, YMF24 and YMF16 (Figure 11-13). 
 
Figure 11 YMF25 800µM in assay buffer, RT ~ 11 minutes 
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Figure 12 YMF24 800µM in assay buffer, RT ~ 12 minutes 
 
Figure 13 YMF16 800µM in assay buffer, RT ~ 10 minutes 
 
 
6.2 Calibration curve – CP20 
In order to quantify the amount of CP20 and the other HPOs in an unknown sample, 
a calibration curve was made using 100 µL injections of increasing concentrations 
(2.5-1000 µM) of CP20 in deionized water. The standard calibration curve for the 
HPOs was produced by running samples in triplicates and integrating the area under 
the curve (AUC) of the chromatograms at 280 nm (Figure 14). The straight line of the 
calibration curve and the R2 value, the coefficient of determination show that the AUC 
levels correlate with the concentrations.  
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Figure 14 - Calibration curve of CP20 
HPLC analysis of CP20 from 2.5 – 1000µM 
 
6.3 HPO BBB Permeability using non-contact co-culture PBEC model 
PBECs were grown in non-contact co-culture, with rat C6 glial cells on the bottom of 
the transwell (i.e. plated on the 12-well plate underneath the Transwell filter). 
Transport across the BBB was determined for the HPOs YMF25, YMF24, YMF16 
and CP20 as a control. The samples for the HPLC were collected from the 
basolateral chamber and apical chamber. Moreover samples of the 800 µM HPO 
solutions were injected in order to determine the amount that was initially added. The 
assay buffer (HBSS, 25mM HEPES, 0.1% BSA, pH 7.4) was injected in order to 
correct the AUC.  
The HPLC results of the samples from the apical chamber showed that only a 
small percentage of the initially added amount was left (Table 1). The most important 
results are those of the basolateral chamber, because they show the amount of the 
HPO that crossed the BBB. The results obtained from the HPLC were corrected 
using the sodium fluorescein transfer via the paracellular route. This value was 
subtracted from the overall transfer, measured by HPLC. For example, in one 
experiment 15.2 % of CP20 was able to penetrate from the apical chamber into the 
basolateral chamber. The HPLC results of the other HPOs show the same pattern 
with only a small percentage left in the apical chamber, between 3-15% in the 
basolateral chamber and the main part of the compounds inside the cells. 
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Table 1 HPO Permeability for PBECs in non-contact co-culture 
  
mean % in apical chamber 
(blood compartment) 
mean % in basolateral chamber 
(brain compartment) 
CP20 0.53 15.17 
YMF25 0.14 11.98 
YMF24 0.41 14.40 
YMF16 0.16 2.92 
 
The results of the basolateral chambers were compared to the in vivo data 
taken from the thesis of Sourav Roy: Iron chelator design: evaluation of blood-brain 
barrier permeability and neuroprotective properties (Roy 2009). 
  
Figure 15 HPO permeability comparison of in vitro (non-contact co-culture) with in vivo data 
The graph shows the permeability of the indicated HPO, obtained from in vitro BBB system using PBECs in non-
contact co-culture with C6 cells as a BBB model (Blue bars) and in vivo BBB permeability using in situ perfusion 
of HPO in mice (Green Bars) conducted by Sourav Roy (Roy 2009). *P < 0.05, ** P < 0.01 when compared to in 
vivo data. 
Both systems showed that CP20, YMF24 and YMF25 are able to cross the 
BBB. YMF16 achieved the lowest penetration in both systems. Statistical analysis 
with GradPad Prism using the unpaired t-test showed that the means of YMF24 and 
YMF16 were not significantly different. However, the means of YMF25 and CP20 
were significantly different. 
6.4 HPO BBB Permeability using contact co-culture PBEC model 
PBECs were grown in contact co-culture, with rat C6 glial cells on the underside of 
the transwell. Transport across the BBB was determined for the HPOs, YMF25, 
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YMF24, YMF16 and CP20 as a control. The samples for the HPLC were collected 
from the basolateral chamber and apical chamber. Moreover samples of the 800 µM 
HPO solutions were injected in order to determine the amount that was initially 
added. The assay buffer (HBSS, 25mM HEPES, 0.1% BSA, pH 7.4) was injected in 
order to correct the AUC.  
The HPLC results of the samples from the apical chamber showed again that 
only a small percentage of the initially added amount was left. In this model around 8-
18% of the HPOs could penetrate into the basolateral chamber (Table 2).  
 
Table 2 HPO Permeability for PBECs in contact co-culture 
  
mean % in apical chamber 
(blood compartment) 
mean % in basolateral chamber 
(brain compartment) 
CP20 0.07 16.38 
YMF25 0.05 6.57 
YMF24 0.20 18.28 
YMF16 0.05 8.52 
 
The results of the basolateral chambers were compared to the in vivo data 
taken from the thesis of Sourav Roy: Iron chelator design: evaluation of blood-brain 
barrier permeability and neuroprotective properties (Roy 2009). 
  
Figure 16 HPO permeability comparison of in vitro (contact co-culture) with in vivo data 
The graph shows the permeability of the indicated HPO, obtained from in vitro BBB system using PBECs in 
contact co-culture with C6 cells as a BBB model (Red bars) and in vivo BBB permeability using in situ perfusion of 
HPO in mice (Green Bars) conducted by Sourav Roy (Roy 2009). *P < 0.05, ** P < 0.01 when compared to in vivo 
data. 
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In both systems, YMF24  achieved the highest concentration in the basolateral 
chamber. However, YMF16 achieved a higher concentration than YMF25 and CP20 
in the in vitro model. Statistical analysis with GradPad Prism using the unpaired t-test 
showed that all means of the HPOs significantly different.  
Furthermore, the results of the contact co-culture were compared with the 
results of the non-contact co-culture. 
  
Figure 17 HPO permeability comparison of both in vitro (contact co-culture and non-contact co culture) systems 
The graph shows the permeability of the indicated HPO, obtained from both in vitro BBB systems using PBECs in 
non-contact co-culture with C6 cells as a BBB model (Blue bars) and contact co-culture (Red Bars) *P < 0.05, ** P 
< 0.01 when compared to non-contact co-culture data. 
Statistical analysis with GradPad Prism using the unpaired t-test showed that 
the means of YMF24, YMF16 and CP20 were not significantly different, only the 
means of YMF25 were significantly different. 
 
 
 
6.5 HPO BBB Permeability using non-contact co-culture PBEC model 
In the last permeability assay PBECs were grown again in non-contact co-culture, 
because the results of this model were more similar to the in vivo-system results. 
Moreover, this model is simpler than the contact co-culture, thus sources of errors 
can be reduced. In this permeability assay the assay buffer did not contain protein 
(BSA), in order to investigate if this would affect the HPLC analysis. Transport across 
the BBB was determined for the HPOs, YMF25, YMF24, YMF16 and CP20 as a 
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control. The samples for the HPLC were collected from the basolateral chamber and 
apical chamber. Moreover samples of the 800 µM HPO solutions were injected in 
order to determine the amount that was initially added. The assay buffer (HBSS, 
25mM HEPES, pH 7.4) was injected in order to correct the AUC.  
The HPLC results of the samples from the apical chamber and basolateral 
chamber are displayed in Table 3. This time a high amount of the HPOs could be 
detected in the apical chamber, which confirms that even a small percentage of 
protein in the assay buffer affects the HPLC analysis.  
Table 3 HPO Permeability for PBECs in non-contact co-culture 
  
mean % in apical chamber 
(blood compartment) 
mean % in basolateral chamber 
(brain compartment) 
CP20 72.04 11.03 
YMF25 82.06 14.28 
YMF24 n/a 20.81 
YMF16 80.42 13.83 
 
The results of the basolateral chambers were compared to the in vivo data 
taken from the thesis of Sourav Roy: Iron chelator design: evaluation of blood-brain 
barrier permeability and neuroprotective properties (Roy 2009). 
  
Figure 18 HPO permeability comparison of in vitro (non-contact co-culture) with in vivo data 
The graph shows the permeability of the indicated HPO, obtained from in vitro BBB system using PBECs in non-
contact co-culture with C6 cells as a BBB model (Blue bars) and in vivo BBB permeability using in situ perfusion 
of HPO in mice (Green Bars) conducted by Sourav Roy (Roy 2009).** P < 0.01, *** P < 0.001 when compared to 
in vivo data. 
Statistical analysis with GradPad Prism using the unpaired t-test showed that 
the means of YMF24 were not significantly different. However, the means of YMF25, 
YMF16 and CP20 were significantly different. 
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Furthermore, the results of the non-contact co-culture were compared with the 
results of the contact co-culture. 
  
Figure 19 HPO permeability comparison of both in vitro (contact co-culture and non-contact co culture) systems 
The graph shows the permeability of the indicated HPO, obtained from both in vitro BBB systems using PBECs in 
non-contact co-culture with C6 cells as a BBB model (Blue bars) and contact co-culture (Red Bars) *P < 0.05, ** P 
< 0.01 when compared to contact co-culture data. 
Statistical analysis with GradPad Prism using the unpaired t-test showed that 
the means of YMF24, YMF16 and CP20 were not significantly different. However, the 
means of YMF25 were significantly different. 
In summary, both in vitro systems, non-contact co-culture and contact co-
culture, are suitable for the permeability assay of HPOs. The comparison of both in 
vitro models with data obtained from in vivo experiments showed similar results. 
Therefore the non-contact co-culture in vitro model should be used for future 
permeability assays, because it is simpler and thus sources of errors can be reduced.  
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7 Discussion 
 
 
The aim of this project was to synthesize an iron chelator, which is coupled with a 
glucose-molecule and test this chelator for its ability to cross the blood-brain barrier 
based on an in vitro system. 
The BBB plays a crucial role in the maintenance of the brain homeostasis and 
prevents toxic and noxious substrates from entering the brain, including >98% of 
drugs, while it ensures a sufficient supply of essential nutrients (Mensch, Oyarzabal 
et al. 2009; Cardoso, Brites et al. 2010). Drug delivery across the BBB is a promising 
field of research, because the increasing number of neurodegenerative diseases, 
such as Alzheimer’s (AD) and Parkinson’s disease (PD), led to the necessity to 
develop drugs, which can cross the BBB (Molina-Holgado, Gaeta et al. 2008; 
Mensch, Oyarzabal et al. 2009). There are many experimental systems, which study 
the function, properties and transport mechanisms of the BBB (Cardoso, Brites et al. 
2010). 
 Iron chelators had been used in diseases with states of iron overload for a 
long time and are considered as a reasonable approach in the treatment of 
neurodegenerative diseases, including AD and PD. Both diseases are associated 
with elevated levels of redox active metals, particularly iron, in the brain, which can 
lead to toxicity (Hider, Roy et al. 2011). Therefore is it of great interest to investigate 
the ability of different iron chelators to cross the blood-brain barrier and reach the 
brain.  
 Unfortunately the synthesis of the desired iron chelator could not be 
completed. Due to the limited time available for my project, it was impossible to 
obtain the desired chelator in acceptable yield and purity. However, a compound was 
produced with the potential to act as a chelator, made at 12% yield, but needs further 
work to increase the purity and yield. The conditions of the coupling reaction, such as 
duration of the coupling and solvents, need to be investigated further. A possibility to 
obtain a pure product could be purification by column chromatography or extraction. 
Furthermore, the conditions for the deprotection need to be investigated further. A 
possible way could be to remove the acetyl groups first. In this order the molecule 
stays more hydrophobic and it should be extracted more easily into CHCl3. Then the 
cleavage of the benzyl ether could be performed by hydrogenation. A chemist of the 
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department of Medicinal Chemistry at King’s College London will continue to work on 
this compound with the aim of obtaining the desired iron chelator in an acceptable 
yield and purity.  
 Therefore four different HPO-derivatives, CP20, YMF25, YMF24 and YMF16 
have been tested on two different in vitro systems. The data of the in vitro systems 
was compared to the data obtained from in vivo experiments performed by Sourav 
Roy (Roy 2009). Even though there have been some difficulties with the HPLC 
analysis, enough valuable data could be produced. The results of my project show, 
that the non-contact co-culture and the contact co-culture are comparable. Moreover 
the results of my experiment comply with the results of the in vivo experiment, which 
confirms the quality of the in vitro systems. Since YMF24 achieved the highest 
results in all systems, in vitro and in vivo, it could be of great interest to continue the 
research on this molecule. Derivatives of this compound could be synthesized and 
tested for their ability to cross the BBB.  
7.1 Changes in the analysis 
As mentioned above, some difficulties appeared with the HPLC analysis. One major 
problem was the small volume from the apical chamber (~400µL) available for 
analysis. The injector needle of the HPLC did not always reach the bottom of the vial 
to take up the whole amount needed for the analysis. This made some of the spectra 
obtained from the apical chamber useless. In order to avoid this problem, the volume 
can be diluted with water or inserts for the HPLC vials can be used. When the 
volume is diluted, errors can occur, because the amount has to be corrected 
afterwards. Moreover, the use of an internal standard would be helpful and ensure 
that the right amount of the compound was injected. The internal standard should be 
a HPO-derivative with similar properties to the ones tested, but a difference in the 
retention time. For this reason CP38 was tested by HPLC analysis, but it is not 
suitable due to the overlapping retention time.  
 In order to obtain more accurate data, a calibration curve should be 
established for each experiment. Moreover it would be interesting to use 100µL 
injections of increasing concentrations of CP20 in assay buffer instead of deionized 
water.   
 One limiting factor of the HPLC analysis is the time needed for one sample. By 
changing the column (PLRP-S, 300 Å, 8µm, 15 cm) for a thinner and smaller column 
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this time could be reduced.  Therefore more samples could be analysed in short time 
and the volume needed would be reduced. Moreover, the faster analysis could 
prevent the samples from precipitation or other time-depending events. 
 In addition, some difficulties appeared with the protein assay, which was 
performed for the non-contact co-culture and contact co-culture. In order to 
determine the intracellular accumulation of the HPOs, any protein within the sample 
should be precipitated with TCA. After the centrifuge no pellet was visible. Therefore 
the samples were analysed by HPLC. The HPLC spectra showed only background 
signals of the buffer. Our conclusion was that the main part of the HPO was bound to 
proteins inside the PBECs, which cannot be determined by HPLC. Another method 
for protein precipitation could be the use of deoxycholate (DOC), acetone, methanol 
or chloroform instead of TCA. However, one permeability assay using the non-
contact co-culture was performed without protein in the assay buffer and the samples 
analysed by HPLC. In contrast to the results of the other permeability assays, HPLC 
spectra of the apical chamber showed high amounts of the HPOs (70-80%). In this 
experiment the results of the apical chamber and the basolateral chamber added up 
to almost 100%. Consequently, even small amounts of protein in the assay buffer 
interfere with the HPLC analysis and lead to false results. This needs to be 
investigated further, in order to determine how much was due to the protein and how 
much was due to HPLC problems, such as injection errors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
8 Abstract 
 
 
The blood-brain barrier (BBB) plays a crucial role in maintaining the health and 
functionality of the central nervous system (CNS). The properties and features of the 
BBB restrict toxic and noxious substrates, such as xenobiotics, from entering the 
brain, but provide a sufficient supply of nutrients that are essential for the proper 
function of the brain. Moreover the BBB prevents > 98% of drugs from entering the 
brain, hindering side effects within the brain, which is advantageous for most drugs 
that are not targeted to the brain. However, increased life expectancies have led to 
an increase in neurodegenerative diseases, such as Alzheimer’s (AD) and 
Parkinson’s (PD) and a need to develop drugs that can enter the CNS. AD and PD 
are associated with elevated levels of redox active metals in the brain, especially 
iron, which can lead to protein aggregation and produce free radicals, such as 
hydroxyl radicals. Therefore, chelation therapy is a reasonable approach to reduce 
the toxic levels of iron, which makes it necessary to design chelating agents that can 
cross the BBB. Presently, chemists’ from Prof Hider’s Group at the King’s College 
London (KCL) are working on synthesising different iron chelators using 3-
hydroxypyridin-4-one (HPO) derivatives that are linked to a glucose molecule, in 
order to enhance the BBB permeability of the chelators, since glucose is the main 
energy source for the brain and therefore is efficiently transported into the brain. The 
aim of my Diploma thesis project was to synthesize an iron chelator, which is coupled 
with a sugar molecule and to analyse this molecule’s ability to cross the BBB with 
alongside other HPO-derivative chelators. 
 The starting material for the chelator synthesis was benzylated maltol, which 
was converted into the 4-pyridinone-derivative through an amine insertion reaction 
using β-alanine and sodium hydroxide. For the coupling reaction with the sugar, the 
4-pyridinone-derivative was converted into an NHS-ester which led to the desired 
compound. The molecule was then purified by repeated extraction. To remove the 
protective groups, benzyl ether and acetic acid ester, the molecule underwent 
hydrogenation followed by the molecule being taken up in sodium hydroxide, 
respectively. Unfortunately, this was not successful and could not be repeated due to 
time restrictions of my project, and so the BBB permeability of the desired compound 
could not be tested with the other test compounds. The BBB permeability of other 
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HPO chelators was assessed using in vitro porcine brain endothelial cells (PBECs) 
co-cultured with glial cells as a BBB model provided by Dr Preston’s research group 
(Pharmacology and Therapeutics, KCL). The compounds were tested on PBECs, 
which were grown with rat C6 glial cell line in non-contact co-culture as well as in 
contact co-culture. The samples of the permeability assay were analysed and 
quantified by HPLC.  
The results of my experiments showed that both experimental systems are 
comparable and future permeability assays can be carried out using the non-contact 
co-culture, which is easier to handle and sources of errors can be reduced. 
Furthermore, a good correlation between the in vitro data obtained here, and in vivo 
data (obtained previously by Dr. Sourav Roy using mice models) was observed, 
which confirms the quality of this experimental system. 
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9 Zusammenfassung 
 
 
Die Bluthirnschranke (BHS) spielt eine entscheidende Rolle für die Gesundheit und 
Funktionalität des zentralen Nervensystems (ZNS). Sie hindert toxische und 
schädliche Substanzen, wie etwa Xenobiotika ins Gehirn zu kommen, stellt jedoch 
sicher, dass das Gehirn mit ausreichend essentiellen Nährstoffen versorgt wird. Des 
Weiteren sorgt die BHS dafür, dass >98% aller Arzneimittel nicht ins Gehirn 
gelangen, wodurch unerwünschte Nebenwirkungen vermieden werden. Diese 
Funktion ist für die Mehrzahl der Arzneistoffe erstrebenswert. Mit der Zunahme der 
Lebenserwartung kam es zu einem Anstieg der neurodegenerativen Erkrankungen, 
wie Alzheimer und Parkinson, einhergehend mit der Notwendigkeit der Entwicklung 
von ZNS-gängigen Arzneimitteln. Es besteht ein Zusammenhang zwischen den 
Erkrankungen, Alzheimer und Parkinson, und erhöhten Werten von redox-aktiven 
Metallen im Gehirn, insbesondere Eisen, welches zur Aggregation von Proteinen und 
der Entstehung von freien Radikalen, wie etwa dem Hydroxyl-Radikal führen kann. 
Chelatbildung ist ein möglicher Ansatz die erhöhten Eisenwerte zu reduzieren und 
führte zur Entwicklung von Chelatoren, welche die BHS überwinden können. Derzeit 
arbeiten Chemiker der Arbeitsgruppe von Prof. Hider des King’s College London an 
der Synthese von Eisenchelatoren, die sich von dem 3-Hydroxypyridin-4-on (HPO) 
ableiten und mit einem Glucosemolekül gekoppelt sind. Durch diese Modifikation soll 
die Permeabilität durch die BHS erhöht werden, da Glucose die Hauptenergiequelle 
des Gehirns ist und effizient ins Gehirn transportiert wird. Ziel meiner Diplomarbeit 
war es einen Eisenchelator zu synthetisieren, der mit einem Zuckermolekül verknüpft 
ist und diesen, neben anderen HPO-Derivaten, auf seine Eignung die BHS zu 
überwinden, zu testen.  
 Ausgangsmaterial für die Synthese des Eisenchelators war benzyliertes 
Maltol, welches durch Zusetzen von β–Alanin und Natronlauge zum 4-Pyridinon-
Derivat umgewandelt wurde. Für die Kopplung mit dem Zucker wurde ein NHS-ester 
aus dem 4-Pyridinon-Derivat hergestellt, der reaktiver ist und die Kupplungsreaktion 
verlief erfolgreich. Das Molekül wurde durch wiederholte Extraktion aufgereinigt. Für 
die Fertigstellung des gewünschten Eisenchelators galt es die Schutzgruppen, 
Benzylether und Essigsäureester, abzuspalten. Der Benzylether wurde mittels 
Hydrierung entfernt und das Molekül anschließend mit Natronlauge behandelt, um 
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die Essigsäureester abzuspalten. Dieser Versuch blieb bedauerlicherweise erfolglos 
und die Reaktionsbedingungen für die Schutzgruppenabspaltung konnten aufgrund 
des limitieren Zeitraums leider nicht weiter erforscht werden. Aus diesen Gründen 
konnte das Molekül nicht mit den anderen HPO-Derivaten auf seine BHS-
permeabilität getestet werden. Die BHS-permabilität der anderen HPO-Chelatoren 
wurde anhand des in vitro Systems bestehend aus Endothelzellen eines 
Schweinegehirns gemeinsam mit Gliazellen von Ratten in non-contact co-culture als 
auch contact co-culture getestet. Beide in vitro Systeme wurden von Dr. Prestons 
Arbeitsgruppe (Pharmacology and Therapeutics, KCL) bereitgestellt. Die Proben des 
Permeabilitätstests wurden mittels HPLC analysiert und quantifiziert.  
Die Ergebnisse der Experimente haben ergeben, dass beide co-culture 
Systeme gleichwertig sind und für weitere Permeabilitätstests das non-contact co-
culture System, welches weniger komplex ist, verwendet werden kann. Des Weiteren 
konnte eine gute Übereinstimmung zwischen den Ergebnissen der in vitro Systeme 
und in vivo Daten (entnommen der Dissertation von Dr. Sourav Roy) beobachtet 
werden, wodurch die Qualität der in vitro Systeme bestätigt wurde.  
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HPLC – AUCs of CP20 in water 
 
 
calibration curve CP20 in deionized 
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concentration AUC average 
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  1483851 1550140,67 
  1678352   
30µM 1705984   
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